

2022 2 Tier Standard - Keystone First VIP Choice

2022 Prior Authorization Criteria

CURRENT AS OF 07/15/2022

ACITRETIN

Products Affected

- *acitretin*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For prophylaxis of skin cancer in patients with previously treated skin cancers who have undergone an organ transplantation the request will be approved. For psoriasis: the patient has documented adequate trials and/or has another documented medical reason for not using at least 2 of the treatment options listed: topical steroids, Tazorac (tazarotene), methotrexate, and cyclosporine. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a dermatologist or an oncologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ACTEMRA

Products Affected

- ACTEMRA ACTPEN
- ACTEMRA SUBCUTANEOUS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For RA: Either 1) Trial of, medical reason for not using, or contraindication to 1 of the following: Enbrel or Humira or 2) If utilized within the past 120 days, approve for continuation of therapy. For pJIA: Either 1) Trial of, medical reason for not using, or contraindication to 1 of the following: Enbrel or Humira or 2) If utilized within the past 120 days, approve for continuation of therapy. For sJIA: approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ACTIMMUNE

Products Affected

- ACTIMMUNE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ADEFOVIR

Products Affected

- *adefovir dipivoxil*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ADEMPAS

Products Affected

- ADEMPAS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use with PDE inhibitor or nitrate therapy |
| Required Medical Information | Documentation of pulmonary arterial hypertension (PAH) WHO Group I and IV classification and PAH Functional Class. Reviewer will verify available patient claim history to confirm patient is not using PDE inhibitors or nitrates. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or cardiologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ALPHA-1 PROTEINASE INHIBITORS

Products Affected

- ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG, 500 MG
- GLASSIA
- PROLASTIN-C
- ZEMAIRA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | 1) Documentation of hereditary alpha1-antitrypsin deficiency as evident by pretreatment serum AAT levels below 11 micrometer/L and progressive FEV1 or FVC decline demonstrating symptomatic lung disease. AND 2) If the medication request is for an Alpha1-Proteinase Inhibitor (human) product other than Prolastin, the patient has a documented medical reason (such as trial, intolerance or contraindication) for not using Prolastin to treat their medical condition. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

AMBRISENTAN

Products Affected

- *ambrisentan*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of pulmonary arterial hypertension (PAH) WHO Group I classification and PAH Functional Class. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or cardiologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

APOKYN

Products Affected

- *apomorphine hcl subcutaneous*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concomitant use with serotonin 5-HT3 receptor antagonists. |
| Required Medical Information | Reviewer will verify available patient claim history to confirm patient is not using 5-HT3 receptor antagonists. If diagnosis is Parkinsons, the patient must have a documented trial of, contraindication to, or medical reason for not using two formulary alternatives such as entacapone, tolcapone, rasagiline, selegiline, carbidopa/levodopa, bromocriptine, pramipexole or ropinirole. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ARCALYST

Products Affected

- ARCALYST

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ARIPIPIRAZOLE LONG ACTING

Products Affected

- ABILIFY MAINTENA INTRAMUSCULAR PREFILLED SYRINGE
- ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION RECONSTITUTED ER
- ARISTADA INITIO
- ARISTADA INTRAMUSCULAR PREFILLED SYRINGE 1064 MG/3.9ML, 441 MG/1.6ML, 662 MG/2.4ML, 882 MG/3.2ML

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | The member has a documented history of receiving oral aripiprazole without any clinically significant side effects. Additionally, the member has a documented trial and failure or medical reason (e.g. intolerance, hypersensitivity or contraindication) for not utilizing one of these therapies to manage their medical condition: Invega Sustenna, Invega Trinza or Risperdal Consta. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

BANZEL

Products Affected

- *rufinamide oral suspension*
- *rufinamide oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | History of familial Short QT syndrome |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using one formulary alternative generic anticonvulsant for appropriate indications. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

BENLYSTA

Products Affected

- BENLYSTA SUBCUTANEOUS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a rheumatologist, nephrologist, or specialist in the treatment of autoimmune disorders. |
| Coverage Duration | New starts: 6 months. Cont of therapy or reauthorization: until end of contract year. |
| Other Criteria | For new starts for systemic lupus erythematosus (SLE): trial of two of the following glucocorticoids, azathioprine, methotrexate, mycophenolate, or hydroxychloroquine, chloroquine, and cyclophosphamide. For continuation of therapy or reauthorization for SLE: documentation of clinical response to therapy (i.e. fewer flares that required steroid treatment, lower average daily oral prednisone dose, improved daily function either as measured through a validated functional scale or through improved daily performance documented at clinic visits, etc. For new starts for lupus nephritis (LN): concurrent use of or medical reason for not using background immunosuppressive therapy regimen. For continuation of therapy or reauthorization for LN: Documentation of improvement in renal function (i.e. reduction in UPCR). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

BENZNIDAZOLE

Products Affected

- *benznidazole*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Patients who have used disulfiram within two weeks of initiation of benznidazole |
| Required Medical Information | Patient has not used disulfiram within two weeks prior to benznidazole initiation per claims history for existing members or attestation from provider for members new to the health plan. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Documentation of a consultation with an infectious disease specialist. |
| Coverage Duration | Request will be authorized for 80 days. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

BESREMI

Products Affected

- BESREMI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a hematologist, oncologist, or specialist for submitted diagnosis. |
| Coverage Duration | The request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

BOSENTAN

Products Affected

- *bosentan*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of pulmonary arterial hypertension (PAH) WHO Group I classification and PAH Functional Class. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or cardiologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

BUDESONIDE ER 9 MG

Products Affected

- *budesonide er oral tablet extended release*
24 hour

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized for 8 weeks. |
| Other Criteria | Patient must have a documented trial of, contraindication to, or medical reason for not using sulfasalazine, balsalazide, or an oral mesalamine product. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

C1 ESTERASE INHIBITOR

Products Affected

- CINRYZE
- HAEGARDA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an allergist, immunologist, rheumatologist, or hematologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

CARBAGLU

Products Affected

- *carglumic acid oral tablet soluble*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

CASPOFUNGIN

Products Affected

- *casposfungin acetate*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Documentation of a consultation with an infectious disease specialist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

CERDELGA

Products Affected

- CERDELGA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Patients with undetermined CYP2D6 metabolizer status. |
| Required Medical Information | Patient's CYP2D6 metabolizer status, as determined by an FDA approved test. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For reauthorization, documentation has been provided that patient has obtained clinical benefit from medication (e.g. increased platelet count, improvement in anemia, PFTs, improvement in radiographic scans, improved quality of life). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

CGRP ANTAGONISTS

Products Affected

- AIMOVIG
- EMGALITY (300 MG DOSE)
- EMGALITY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist, headache specialist, or pain specialist. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | New starts for migraine prophylaxis: 1) at least 4 migraine days per month or one or more severe migraines lasting for greater than 12 hours despite use of abortive therapy (e.g. triptans or NSAIDs) and 2) trial of, contraindication to, or medical reason for not using at least two of the following agents: a beta adrenergic blocker, an anti-epileptic agent, a tricyclic antidepressant, or a serotonin-norepinephrine reuptake inhibitor. For continuation of therapy or reauthorization for migraine prophylaxis (after 6 month start): reduction of at least 1 headache day per month from baseline. New starts on Emgality for episodic cluster headache: trial of, contraindication to, or medical reason for not using verapamil for at least 4 weeks at minimum effective doses. For continuation of therapy or reauthorization for Emgality for episodic cluster headache: reduction in the frequency of headaches (clinical benefit). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

CHOLBAM

Products Affected

- CHOLBAM

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a hepatologist or gastroenterologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

CIBINQO

Products Affected

- CIBINQO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For atopic dermatitis: trial of, contraindication to, or medical reason for not using Rinvoq. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

CIMZIA

Products Affected

- CIMZIA PREFILLED SUBCUTANEOUS PREFILLED SYRINGE KIT
- CIMZIA STARTER KIT SUBCUTANEOUS PREFILLED SYRINGE KIT
- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For RA: Either 1) Trial of, medical reason for not using, or contraindication to 1 of the following: Enbrel or Humira or 2) If utilized within the past 120 days, approve for continuation of therapy. For PsA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Cosentyx, Tremfya, Xeljanz, Rinvoq, Enbrel, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For psoriasis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Cosentyx, Skyrizi, Tremfya, Enbrel, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For ankylosing spondylitis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Cosentyx, Enbrel, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For non-radiographic axial spondyloarthritis: approve. For Crohns Disease: Either 1) Trial of, medical reason for not using, or contraindication to Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |

Formulary ID 22453

Last Updated: 07/2022

| PA Criteria | Criteria Details |
|-----------------------|-------------------------|
| Off-Label Uses | N/A |

CLOBAZAM

Products Affected

- *clobazam oral suspension*
- *clobazam oral tablet*
- SYMPAZAN

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using one formulary alternative generic anticonvulsant for appropriate indications. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

CORLANOR

Products Affected

- CORLANOR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Blood pressure less than 90/50 mmHg |
| Required Medical Information | New starts for chronic heart failure must have all of the following: 1) LVEF of 35% or less 2) Sinus rhythm and have resting heart rate greater than or equal to 70 bpm 3) Blood pressure greater than or equal to 90/50 mmHg, and 4) Trial of, contraindication to, or medical reason for not receiving a beta blocker. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a cardiologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

CORTROPHIN

Products Affected

- CORTROPHIN

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | New starts for MS exacerbation, rheumatic disorders, collagen diseases, dermatologic diseases, serum sickness, edematous state (e.g. nephrotic syndrome without uremia), and respiratory diseases: trial of, contraindication to, or medical reason for not using oral corticosteroids. New starts for ophthalmic disease: trial of, contraindication to, or medical reason for not using oral or ophthalmic corticosteroids. Continuation of therapy or reauthorization for MS exacerbation: documentation of symptom improvement and current use of a multiple sclerosis disease modifying agent for maintenance therapy. Continuation of therapy or reauthorization for all other conditions: documented evidence of response to treatment and symptom improvement. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | MS exacerbation: 1 month. Other conditions: new start for 3 months and reauth end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

COSENTYX

Products Affected

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)
- COSENTYX SENSOREADY PEN
- COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML
- *cosentyx subcutaneous solution prefilled syringe 75 mg/0.5ml*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For PsA or psoriasis: approve. For ankylosing spondylitis: Trial of, medical reason for not using, or contraindication to naproxen. For nonradiographic axial spondyloarthritis: approve. For enthesitis-related arthritis: approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

CYSTAGON

Products Affected

- CYSTAGON

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

DALFAMPRIDINE ER

Products Affected

- *dalfampridine er*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | History of seizure or moderate/severe renal impairment (CrCl 50 mL/min or less). |
| Required Medical Information | For new starts: 1) Attestation that creatinine clearance (CrCl) greater than 50 mL/min was confirmed prior to initiation of therapy, AND 2) Documentation has been provided that member is ambulatory (able to walk at least 25 feet) and has a documented walking impairment, AND 3) For appropriate indications, member is currently being treated with a disease modifying agent (e.g. immunomodulator, interferon, etc.) or has a medical reason why member is unable to use a disease modifying agent for their condition. For continuation of therapy or re-authorization requests: 1) Member must experience improvement in walking from baseline due to use of dalfampridine ER. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

DEFERASIROX

Products Affected

- *deferasirox*
- *deferasirox granules*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Patients with GFR less than 40 mL/min/1.73 m ² or patients with platelet counts less than 50,000/mm ³ . |
| Required Medical Information | For all indications: platelet count greater than 50,000/mm ³ (within 30 days) and GFR greater than 40 mL/min/1.73 m ² . For chronic iron overload due to transfusions: serum ferritin concentration greater than 1000 mcg/L (lab result with 30 days). For chronic iron overload in non-transfusion-dependent thalassemia syndromes: serum ferritin concentration greater than 300 mcg/L (lab result with 30 days). |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For deferasirox granules oral packets or deferasirox oral soluble tablets, trial of, contradiction to, or medical reason for not using deferasirox tablets. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

DEPEN

Products Affected

- *penicillamine oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For RA: Trial of, medical reason for not using, or contraindication to 1 of the following: Enbrel or Humira. For other indications, approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

DIACOMIT

Products Affected

- DIACOMIT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using one formulary generic anticonvulsant for appropriate indications. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

DIFICID

Products Affected

- DIFICID

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized for 10 days. |
| Other Criteria | Documentation of prior use, or a medical reason for being unable to use oral vancomycin for current infection. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

DOPTELET

Products Affected

- DOPTELET

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts for chronic liver disease and chronic immune thrombocytopenia (chronic ITP): documented baseline platelet count of less than 50,000/mcL. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with hematologist, hepatologist or surgeon. |
| Coverage Duration | For thrombocytopenia with CLD getting procedure: 5 days. For chronic ITP: remainder of contract year |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

DOXEPIN CREAM

Products Affected

- *doxepin hcl external*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of trial of, contraindication to, or medical reason for not using a topical corticosteroid. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

DUPIXENT

Products Affected

- DUPIXENT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | New starts will be approved for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | New starts for atopic dermatitis: trial of, contraindication to, or medical reason for not using: 1) topical tacrolimus or pimecrolimus and 2) Eucrisa. New starts for asthma with eosinophilic phenotype: 1) blood eosinophil count greater than or equal to 150 cells per microliter, and 2) symptoms persist with at least 1 exacerbation in the last 12 months requiring additional treatment (e.g. oral systemic steroids) while on a high dose inhaled corticosteroid with a long-acting B2 agonist. New starts for oral corticosteroid asthma: symptoms persist with at least 1 exacerbation in the last 12 months requiring additional treatment, (e.g. oral systemic steroids) while on a high dose inhaled corticosteroid with a long-acting B2 agonist. New starts for chronic rhinosinusitis with nasal polyps: trial of, contraindication to, or medical reason for not using nasal corticosteroids. Continuation of therapy or reauthorization for all indications: clinical benefit from use of the drug. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

EGRIFTA

Products Affected

- EGRIFTA SV

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of active antiretroviral therapy for at least 8 weeks. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

EMPAVELI

Products Affected

- EMPAVELI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a hematologist, nephrologist, oncologist, or other appropriate specialist. |
| Coverage Duration | New starts: 3 months. Cont. of therapy or reauthorization: until end of contract year. |
| Other Criteria | For new starts, all of the following must be provided: 1) Documentation of vaccination against meningococcal disease or a documented medical reason why the patient cannot receive vaccination or vaccination needs to be delayed, 2) Documentation that antimicrobial prophylaxis with oral antibiotics (such as penicillin, macrolides, ciprofloxacin, etc.) for two weeks has been provided if the meningococcal vaccine is administered less than 2 weeks before starting therapy or a documented medical reason why the patient cannot receive oral antibiotic prophylaxis, 3) Documentation of diagnosis by high sensitivity flow cytometry, AND 4) Documentation of Hemoglobin (Hgb) less than 10.5 g/dL. For continuation of therapy or reauthorization, documentation of clinical response to therapy (e.g., increased Hgb, reduced need for blood transfusions, improvement in quality of life scores). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ENBREL

Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For RA: Trial of, medical reason for not using, or contraindication to 1 disease modifying antirheumatic drug (DMARD) (methotrexate, leflunomide, or sulfasalazine). For pJIA: Trial of, medical reason for not using, or contraindication to 1 of the following DMARDs: methotrexate or leflunomide. For PsA or psoriasis: approve. For ankylosing spondylitis: Trial of, medical reason for not using, or contraindication to naproxen. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ENDARI

Products Affected

- ENDARI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation that two or more painful sickle cell crises have occurred in the past 12 months. Trial of, contraindication to, or medical reason for not using hydroxyurea for at least three months. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a hematologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

EPIDIOLEX

Products Affected

- EPIDIOLEX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using one formulary generic anticonvulsant for appropriate indications. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

EPRONTIA

Products Affected

- EPRONTIA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | The request will be authorized until the end of the contract year. |
| Other Criteria | Documented trial of, contraindication to, or medical reason for not using topiramate. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ERYTHROPOETIN STIMULATING AGENTS

Products Affected

- ARANESP (ALBUMIN FREE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 40 MCG/ML, 60 MCG/ML
- ARANESP (ALBUMIN FREE) INJECTION SOLUTION PREFILLED SYRINGE
- EPOGEN INJECTION SOLUTION 10000 UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML
- PROCIT
- RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 10000 UNIT/ML(1ML), 2000 UNIT/ML, 20000 UNIT/ML, 3000 UNIT/ML, 4000 UNIT/ML, 40000 UNIT/ML

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts for all indications: Hgb less than 10 g/dL or within compendia range for treatment of the requested medical condition. If the request for Epogen, Procrit, or Aranesp, trial of, contraindication to, or medical reason for not using Retacrit for appropriate indications. For continuation of therapy or re-authorization: Hgb must not exceed 10 g/dL (anemia related to cancer), 11 g/dL (anemia of CKD), 12 g/dL (zidovudine-related anemia in members with HIV and ribavirin-induced anemia), 13 g/dL (elective, noncardiac, nonvascular surgery needing red blood cell allogeneic transfusion reduction). |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized for 6 months. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ESBRIET

Products Affected

- ESBRIET
- *pirfenidone*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For diagnosis of idiopathic pulmonary fibrosis: documentation of confirmation of diagnosis on high resolution CT scan or through lung biopsy. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or lung transplant specialist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

EUCRISA

Products Affected

- EUCRISA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a dermatologist, immunologist or an allergist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using topical tacrolimus or pimecrolimus. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

EVRYSDI

Products Affected

- EVRYSDI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For new starts, all of the following must be included: 1) Documentation of genetic testing confirming diagnosis AND 2) Documentation of baseline motor function or motor milestone achievement [e.g. CHOP Infant Test of Neuromuscular Disorders (CHOP-INTEND) or Hammersmith Infant Neurological Examination (HINE) for Type 1 or Hammersmith Functional Motor Scale Expanded Scores (HFMSE) for Type II and Type III, or 6 minute walk test in subjects able to walk]. For continuation of therapy or reauthorization, documentation of clinical response has been submitted (e.g. improvement in motor function/motor milestone achievement scores using CHOP-INTEND or HFMSE, 6 minute walk test or HINE improvement in more categories of motor milestones than worsening, patient remains permanent ventilation free if no prior ventilator support). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

FASENRA

Products Affected

- FASENRA
- FASENRA PEN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | New starts will be approved for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | New starts for severe asthma with an eosinophilic phenotype: 1) blood eosinophil count greater than or equal to 150 cells per microliter within 6 weeks or 300 cells per microliter within 12 months, AND 2) symptoms persist with at least 1 exacerbation in the last 12 months requiring additional treatment (e.g. oral systemic steroids) while on a high dose inhaled corticosteroid with a long-acting B2 agonist. Continuation of therapy or re-authorization for severe asthma with an eosinophilic phenotype: clinical benefit from use of the drug. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

FENTANYL CITRATE TRANSMUCOSAL PRODUCTS

Products Affected

- *fentanyl citrate buccal lozenge on a handle*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation must be provided for the all of the following: 1) fentanyl citrate oral transmucosal is being prescribed to treat cancer-related breakthrough pain AND 2) Patient has been taking opioids at a dose equal to 60 MME per day for at least one week. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

FERRIPROX

Products Affected

- *deferiprone*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For new starts: 1) serum ferritin level above 1,000 mcg/L and absolute neutrophil count (ANC) greater than $1.5 \times 10^9/L$ within 30 days of request, and 2) Trial of, contraindication to, or medical reason for not using deferasirox tablets. For continuation of therapy or reauthorization, decrease in serum ferritin from baseline. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

FINTEPLA

Products Affected

- FINTEPLA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using one formulary generic anticonvulsant for appropriate indications. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

FIRDAPSE

Products Affected

- FIRDAPSE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | History of seizures. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

GALAFOLD

Products Affected

- GALAFOLD

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

GATTEX

Products Affected

- GATTEX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Provider is a gastroenterologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

GNRH AGONISTS

Products Affected

- CAMCEVI
- ELIGARD
- FIRMAGON (240 MG DOSE)
- FIRMAGON SUBCUTANEOUS SOLUTION RECONSTITUTED 80 MG
- LUPRON DEPOT (1-MONTH)
- LUPRON DEPOT (3-MONTH)
- LUPRON DEPOT (4-MONTH)
- LUPRON DEPOT (6-MONTH)
- LUPRON DEPOT-PED (1-MONTH) INTRAMUSCULAR KIT 7.5 MG
- LUPRON DEPOT-PED (3-MONTH) INTRAMUSCULAR KIT 11.25 MG (PED)
- TRELSTAR MIXJECT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | If the medication request is for the treatment of prostate cancer and if the request is for any other GnRH agonist other than Eligard, the patient must have a documented trial of, contraindication to, or medical reason for not using Eligard to treat their prostate cancer. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

GOCOVRI

Products Affected

- GOCOVRI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | New starts: trial of, contraindication to, or medical reason for not using generic amantadine. Continuation of therapy or reauthorization: Member demonstrates clinical benefit (i.e. improvement in levodopa-induced dyskinesia or decreased off episodes). |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist. |
| Coverage Duration | New starts will be authorized for 3 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

GROWTH HORMONES

Products Affected

- GENOTROPIN MINIQUICK SUBCUTANEOUS PREFILLED SYRINGE
- GENOTROPIN SUBCUTANEOUS CARTRIDGE
- HUMATROPE INJECTION CARTRIDGE
- NORDITROPIN FLEXPRO SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 10 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 20 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- NUTROPIN AQ NUSPIN 5 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- OMNITROPE SUBCUTANEOUS SOLUTION CARTRIDGE
- OMNITROPE SUBCUTANEOUS SOLUTION RECONSTITUTED
- SKYTROFA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts for growth hormone deficiency: 1) If the request is not for Genotropin, trial of, contraindication to, or medical reason for not using Genotropin, 2) documentation showing bone age testing, height, weight, and Growth Hormone Stimulation Test results OR Insulin Growth Factor 1 level. For continuation of therapy or reauthorization for growth hormone deficiency: documentation (medical records) showing positive response to treatment. For requests for all other medically accepted indications other than growth hormone deficiency, the request will be approved for products other than Skytrofa. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an endocrinologist or nephrologist. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

H. P. ACTHAR

Products Affected

- ACTHAR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | New starts for MS exacerbation, rheumatic disorders, collagen diseases, dermatologic diseases, serum sickness, edematous state (e.g. nephrotic syndrome without uremia), and respiratory diseases: trial of, contraindication to, or medical reason for not using oral corticosteroids. New starts for ophthalmic disease: trial of, contraindication to, or medical reason for not using oral or ophthalmic corticosteroids. Continuation of therapy or reauthorization for MS exacerbation: documentation of symptom improvement and current use of a multiple sclerosis disease modifying agent for maintenance therapy. Continuation of therapy or reauthorization for all other conditions: documented evidence of response to treatment and symptom improvement. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | MS exacerbation: 1 month. Other conditions: new start for 3 months and reauth end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

HETLIOZ

Products Affected

- HETLIOZ
- HETLIOZ LQ

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Provider is a sleep specialist or neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

HIGH DOSE OPIOID

Products Affected

- *fentanyl transdermal patch 72 hour 100 mcg/hr*
- *methadone hcl oral tablet 10 mg*
- *morphine sulfate er oral tablet extended release 100 mg, 200 mg*
- *oxycodone hcl er oral tablet er 12 hour abuse-deterrent*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Members being treated for active cancer diagnoses, sickle cell diagnoses, those in hospice care, or receiving palliative care will be approved. For new starts, ALL of the following are required: (1) Taking opioids at a dose equal to 60 MME per day for at least one week, (2) Current regimen is the lowest possible effective dose of opioid therapy, (3) If member is on concurrent benzodiazepines and/or muscle relaxant therapy, the prescriber attests that concurrent therapy is medically necessary (4) Member is not being treated for substance abuse with buprenorphine-containing products. For continuing therapy, ALL of the following are required: (1) Member's pain has been assessed within the last 6 months, (2) Member has demonstrated clinical improvement in pain and function on current medication regimen, (3) If member is on concurrent benzodiazepines and/or muscle relaxant therapy, the prescriber attests that concurrent therapy is medically necessary, (4) Member is not being treated for substance abuse with buprenorphine-containing products. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

HIGH RISK MEDICATION

Products Affected

- *clemastine fumarate oral tablet 2.68 mg*
- *cyproheptadine hcl oral*
- *dipyridamole oral*
- *disopyramide phosphate oral*
- *ergoloid mesylates oral*
- *glyburide micronized oral tablet 1.5 mg, 3 mg, 6 mg*
- *glyburide oral tablet 1.25 mg, 2.5 mg, 5 mg*
- *glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg*
- *glyburide-metformin oral tablet 5-500 mg*
- *guanfacine hcl er*
- *guanfacine hcl oral*
- *hydroxyzine hcl oral syrup*
- *hydroxyzine hcl oral tablet 25 mg, 50 mg*
- *hydroxyzine pamoate oral*
- *indomethacin er*
- *indomethacin oral capsule 25 mg, 50 mg*
- *ketorolac tromethamine oral*
- *megestrol acetate oral suspension 40 mg/ml, 400 mg/10ml, 625 mg/5ml*
- *meperidine hcl oral solution*
- *meperidine hcl oral tablet 50 mg*
- *methyldopa oral*
- *nifedipine oral*
- **NORPACE CR**
- *pentazocine-naloxone hcl*
- *promethazine hcl oral*
- *promethazine hcl rectal suppository 12.5 mg, 25 mg*
- *promethazine vc*
- *promethazine-phenylephrine*
- **PROMETHEGAN RECTAL SUPPOSITORY 50 MG**
- *trihexyphenidyl hcl*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For patients 65 years old and older the prescriber has documented: 1) the benefits of treatment with the drug outweigh the potential risks identified for people 65 years old and older, and 2) the risks and side effects have been discussed and will be monitored. |
| Age Restrictions | Prior authorization only applies to members 65 years old or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------|
| Off-Label Uses | N/A |

HIGH RISK MEDICATION - PROTECTED CLASS DRUGS

Products Affected

- *amitriptyline hcl oral*
- *amoxapine*
- *clomipramine hcl oral*
- *doxepin hcl oral capsule*
- *doxepin hcl oral concentrate*
- *imipramine hcl oral*
- *imipramine pamoate*
- *megestrol acetate oral tablet*
- MENEST ORAL TABLET 0.3 MG, 0.625 MG, 1.25 MG
- *perphenazine-amitriptyline*
- *phenobarbital oral elixir*
- *phenobarbital oral tablet*
- *protriptyline hcl*
- *trimipramine maleate oral*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For patients 65 years old and older the prescriber has documented: 1) the benefits of treatment with the drug outweigh the potential risks identified for people 65 years old and older, and 2) the risks and side effects have been discussed and will be monitored. |
| Age Restrictions | Prior authorization only applies to members 65 years old or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

HIGH RISK MEDICATION, BUTALBITAL

Products Affected

- ASCOMP-CODEINE
- BAC
- *butalbital-acetaminophen oral tablet 50-325 mg*
- *butalbital-apap-caff-cod oral capsule 50-325-40-30 mg*
- *butalbital-apap-caffeine oral capsule 50-325-40 mg*
- *butalbital-apap-caffeine oral tablet 50-325-40 mg*
- *butalbital-asa-caff-codeine*
- *butalbital-asa-caffeine*
- *butalbital-aspirin-caffeine oral capsule*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For patients 65 years old and older the prescriber has documented: 1) the benefits of treatment with the drug outweigh the potential risks identified for people 65 years old and older, and 2) the risks and side effects have been discussed and will be monitored. |
| Age Restrictions | Prior authorization only applies to members 65 years old or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

HIGH RISK MEDICATION, DIGOXIN

Products Affected

- DIGITEK ORAL TABLET 250 MCG
- DIGOX ORAL TABLET 250 MCG
- *digoxin oral solution*
- *digoxin oral tablet 250 mcg*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For patients 65 years old and older the prescriber has documented: 1) the benefits of treatment with the drug outweigh the potential risks identified for people 65 years old and older, 2) the risks and side effects have been discussed and will be monitored, and 3) trial of or medical reason for not using digoxin doses up to 0.125 mg per day. |
| Age Restrictions | Prior authorization only applies to members 65 years old or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

HIGH RISK MEDICATION, SHORT TERM MUSCLE RELAXANT

Products Affected

- *carisoprodol oral*
- *carisoprodol-aspirin-codeine*
- *chlorzoxazone oral tablet 500 mg*
- *cyclobenzaprine hcl oral tablet 10 mg, 5 mg*
- *metaxalone oral tablet 800 mg*
- *methocarbamol oral*
- *orphenadrine citrate er*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For patients 65 years old and older the prescriber has documented: 1) the benefits of treatment with the drug outweigh the potential risks identified for people 65 years old and older, and 2) the risks and side effects have been discussed and will be monitored. |
| Age Restrictions | Prior authorization only applies to members 65 years old or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | New starts will be authorized for 30 days. Continuation of therapy or reauth will be for 90 days. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

HIGH RISK MEDICATION, SLEEP AGENTS

Products Affected

- *eszopiclone*
- *temazepam*
- *zaleplon*
- *zolpidem tartrate er*
- *zolpidem tartrate oral tablet 10 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For patients 65 years old and older the prescriber has documented: 1) the benefits of treatment with the drug outweigh the potential risks identified for people 65 years old and older, and 2) the risks and side effects have been discussed and will be monitored. For zolpidem immediate release 10mg and zolpidem ER: trial of or medical reason for not using zolpidem immediate release 5mg. |
| Age Restrictions | Prior authorization only applies to members 65 years old or older. |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

HUMIRA

Products Affected

- HUMIRA PEDIATRIC CROHNS START SUBCUTANEOUS PREFILLED SYRINGE KIT 80 MG/0.8ML, 80 MG/0.8ML & 40MG/0.4ML
- HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT
- HUMIRA PEN-CD/UC/HS STARTER
- HUMIRA PEN-PEDIATRIC UC START
- HUMIRA PEN-PS/UV/ADOL HS START SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.8ML
- HUMIRA PEN-PSOR/UEVIT STARTER
- HUMIRA SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For RA: Trial of, medical reason for not using, or contraindication to 1 disease modifying antirheumatic drug (DMARD) (methotrexate, leflunomide, or sulfasalazine). For pJIA: Trial of, medical reason for not using, or contraindication to 1 of the following DMARDs: methotrexate or leflunomide. For ankylosing spondylitis: Trial of, medical reason for not using, or contraindication to naproxen. For Crohns Disease: Trial of, medical reason for not using, or contraindication to 1 of the following: mercaptopurine, azathioprine, or corticosteroid (e.g., prednisone, methylprednisolone). For UC: Trial of, medical reason for not using, or contraindication to 1 of the following conventional therapies: mercaptopurine, an aminosalicylate (i.e. mesalamine, sulfasalazine, azathioprine), or a corticosteroid (i.e. prednisone, methylprednisolone). For PsA, psoriasis, Hidradenitis Suppurativa, or Uveitis: approve. |
| Indications | All Medically-accepted Indications. |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------|
| Off-Label Uses | N/A |

ICATIBANT

Products Affected

- *icatibant acetate*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an immunologist, allergist, rheumatologist, or hematologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ILARIS

Products Affected

- ILARIS SUBCUTANEOUS SOLUTION

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For sJIA: approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ILUMYA

Products Affected

- ILUMYA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For psoriasis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Cosentyx, Skyrizi, Tremfya, Enbrel, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

INCRELEX

Products Affected

- INCRELEX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a pediatric endocrinologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

INTRON-A

Products Affected

- INTRON A

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

INVEGA TRINZA

Products Affected

- INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273 MG/0.88ML, 410 MG/1.32ML, 546 MG/1.75ML, 819 MG/2.63ML

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Documented treatment with Invega Sustenna for at least 4 months. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

KALYDECO

Products Affected

- KALYDECO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Combination use with Orkambi, Symdeko, or Trikafta. |
| Required Medical Information | Documentation of CFTR gene that is responsive to ivacaftor treatment. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or an expert in the treatment of cystic fibrosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

KEVEYIS

Products Affected

- KEVEYIS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | New starts: trial of, contraindication to, or medical reason for not using acetazolamide. Continuation of therapy or reauthorization: documentation of clinical improvement with therapy. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a geneticist, neurologist, or endocrinologist. |
| Coverage Duration | New starts will be authorized for 2 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

KEVZARA

Products Affected

- KEVZARA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For RA: Either 1) Trial of, medical reason for not using, or contraindication to 1 of the following: Enbrel or Humira or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

KINERET

Products Affected

- KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For RA: Either 1) Trial of, medical reason for not using, or contraindication to 1 of the following: Enbrel or Humira or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

KORLYM

Products Affected

- KORLYM

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | For all members patient must not be currently on simvastatin, lovastatin, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus. |
| Required Medical Information | Reviewer will verify available claim history to confirm member is not taking simvastatin, lovastatin, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus or tacrolimus concurrently with Korlym. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

KYNMOBI

Products Affected

- KYNMOBI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Kynmobi (apomorphine hydrochloride) is contraindicated in concomitant use with serotonin 5-HT ₃ receptor antagonists. |
| Required Medical Information | Reviewer will verify available patient claim history to confirm patient is not using 5-HT ₃ receptor antagonists. For Parkinsons: trial of, contraindication to, or medical reason for not using two formulary alternatives such as entacapone, tolcapone, rasagiline, selegiline, carbidopa/levodopa, bromocriptine, pramipexole or ropinirole. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

LAMPIT

Products Affected

- LAMPIT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Documentation of a consultation with an infectious disease specialist. |
| Coverage Duration | Request will be authorized for 90 days. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

LIVMARLI

Products Affected

- LIVMARLI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a gastroenterologist or hepatologist. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For new starts: 1) Trial of, contraindication to, or medical reason for not using both of the following: cholestyramine AND rifampin. 2) Prescriber attests that the member has cholestasis 3) Baseline serum bile acid level is provided. 4) Documentation of patients weight. For continuation of therapy or reauthorization: 1) Documentation submitted indicating the member has had all of the following: an improvement in pruritis (e.g. improved observed scratching, decreased sleep disturbances/nighttime awakenings due to scratching, etc.) AND reduction in serum bile acid level from baseline. 2) Prescriber attests that patient has had no evidence of hepatic decompensation (e.g. variceal hemorrhage, ascites, hepatic encephalopathy, portal hypertension, etc.). 3) Documentation of patients weight. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

LUCEMYRA

Products Affected

- LUCEMYRA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For initial therapy, patient must have documented trial of, contraindication to, or medical reason for not using clonidine. Reauthorization criteria: chart notes that show positive response to prior treatment. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized for 14 days. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

LUPKYNIS

Products Affected

- LUPKYNIS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concurrent use with cyclophosphamide. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be rheumatologist, nephrologist, or other specialist in the treatment of autoimmune disorders. |
| Coverage Duration | New starts: 6 months. Cont. of therapy or reauthorization: until end of contract year. |
| Other Criteria | For new starts: 1) Documentation of urine protein/creatinine ratio (UPCR), 2) Documentation that the member has a baseline eGFR greater than 45 mL/min/1.73m ² or that benefit outweighs risk of using this medication at current eGFR, and 3) Concurrent use of or medical reason for not using background immunosuppressive therapy regimen. For continuation of therapy or reauthorization: Documentation of improvement in renal function (i.e. reduction in UPCR or no confirmed decrease from baseline eGFR greater than or equal to 20%). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

LYBALVI

Products Affected

- *lybalvi*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use with opioids. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | 1) Attestation from the provider that the member has had an opioid-free period of a minimum of 7 days after last use of shorting-acting opioids and 14 days from last use of long-acting opioids before initiating Lybalvi, AND 2) Documented trial of, contraindication to, or medical reason for not using at least two generic antipsychotics, one of which must be generic olanzapine. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

MAVYRET

Products Affected

- *mavyret oral packet*
- MAVYRET ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Labs within 3 months of request: liver function tests, detectable HCV RNA viral load. In addition, documentation of genotype, treatment history, and if cirrhotic, documentation of compensated or decompensated cirrhosis. Prescriber attests to completing HBV screening and agrees to monitor for HBV reactivation if patient has a history of HBV infection. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a hepatologist, gastroenterologist, infectious disease specialist, or transplant specialist. |
| Coverage Duration | Request will be authorized for 8-16 weeks as per AASLD-IDSA guidance. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

METHOXSALLEN

Products Affected

- *methoxsalen rapid*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

METHYLTESTOSTERONE

Products Affected

- *methyltestosterone oral*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

METYROSINE

Products Affected

- *metyrosine*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of one of the following: 1) Concurrent use of alpha adrenergic blockers, 2) Medical reason for being unable to use an alpha adrenergic blocker, OR 3) Patient is not a candidate for surgical resection and requires long term treatment with metyrosine. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

MIGLUSTAT

Products Affected

- *miglustat*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts, documentation of diagnosis for mild to moderate type 1 Gaucher disease. For continuation of therapy or reauthorization: documentation of clinical benefit from use of the drug (i.e. increased platelet count, improvement in anemia, PFT's, improvement in radiographic scans, improved quality of life). |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a specialist in treatment of Gaucher's disease. |
| Coverage Duration | Request will be authorized for 6 months. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

MULTIPLE SCLEROSIS AGENTS

Products Affected

- AUBAGIO
- BAFIERTAM
- BETASERON SUBCUTANEOUS KIT
- *dimethyl fumarate oral*
- *dimethyl fumarate starter pack*
- EXTAVIA SUBCUTANEOUS KIT
- GILENYA ORAL CAPSULE 0.5 MG
- *glatiramer acetate*
- GLATOPA
- KESIMPTA
- MAYZENT
- MAYZENT STARTER PACK
- PONVORY
- PONVORY STARTER PACK
- REBIF REBIDOSE SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- REBIF REBIDOSE TITRATION PACK SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- REBIF SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- REBIF TITRATION PACK SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ZEPOSIA
- ZEPOSIA 7-DAY STARTER PACK
- ZEPOSIA STARTER KIT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | If the medication request is for glatiramer, Glatopa, or dimethyl fumarate, the request will be approved. If the request is not for glatiramer, Glatopa, or dimethyl fumarate for multiple sclerosis, the member must have a documented trial of, contraindication to or a medical reason for not using both dimethyl fumarate AND glatiramer or Glatopa. If the request is for Zeposia for ulcerative colitis: Either 1) Trial of, medical reason for not using, or contraindication Humira or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

MYFEMBREE

Products Affected

- MYFEMBREE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Patient has history of osteoporosis or hepatic impairment. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an obstetrician-gynecologist. |
| Coverage Duration | New starts: 6 months. Cont. of therapy or reauthorization: until end of contract year. |
| Other Criteria | For new starts: Trial of, contraindication to, or medical reason for not using an estrogen-progestin contraceptive therapy. For new starts if one of the following drugs has been tried previously, a trial of estrogen-progestin contraceptive therapy is not required: gonadotropin-releasing hormone (GnRH) agonists or tranexamic acid. For continuation of therapy or reauthorization both of the following are required: 1) Treatment does not exceed the eligible maximum lifetime treatment duration of 2 years, and 2) Documentation has been provided that the member has obtained clinical benefit from medication (e.g. reduced menstrual bleeding from baseline). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

NASAL ANTISEIZURE AGENTS

Products Affected

- NAYZILAM
- VALTOCO 10 MG DOSE
- VALTOCO 15 MG DOSE
- VALTOCO 20 MG DOSE
- VALTOCO 5 MG DOSE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Provider attests that diazepam rectal gel cannot be used. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

NATPARA

Products Affected

- NATPARA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of serum calcium greater than 7.5 mg/dL and vitamin D level (within 30 days of request). |
| Age Restrictions | N/A |
| Prescriber Restrictions | Provider is an endocrinologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

NEXLETOL

Products Affected

- NEXLETOL

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a cardiologist, endocrinologist, or a specialist in treatment of lipid disorders. |
| Coverage Duration | New starts will be authorized for 4 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | <p>For new starts ALL of the following must be provided: 1) Documentation of baseline low density lipoprotein cholesterol (LDL-C) 2) Member has tried and failed a high-intensity statin (i.e. atorvastatin 40-80 mg, rosuvastatin 20-40 mg) at maximum tolerated dose for 3 months via claim history or chart notes OR documentation has been provided that the member is not able to tolerate a statin 3) Member has tried and failed ezetimibe at a maximum tolerated dose or documentation has been provided that the patient is not able to tolerate ezetimibe AND 4) Member will continue on maximum tolerated statin dose and ezetimibe dose while receiving Nexletol or documentation has been provided that the member is not able to tolerate a statin and/or ezetimibe. In addition to the initial criteria above if the new start is for the diagnosis of hyperlipidemia and atherosclerotic cardiovascular disease (ASCVD), the following are required: 1) Documentation of history of least one of the following: myocardial infarction or acute coronary syndrome, stroke or transient ischemic attack, coronary artery disease with stable angina, coronary or other arterial revascularization, peripheral vascular disease, or aortic aneurysm AND 2) Member must have a fasting LDL-C greater than or equal to 70 mg/dL. For continuation of therapy or reauthorization requests for all indications: 1) Documentation provided that the member has obtained clinical benefit from medication (e.g. LDL-C lowering from baseline) AND 2) Member will continue on maximum tolerated statin and</p> |

Formulary ID 22453

Last Updated: 07/2022

| PA Criteria | Criteria Details |
|-----------------------|---|
| | ezetimibe dose while receiving Nexletol or documentation has been provided that the member is not able to tolerate a statin and/or ezetimibe. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

NEXLIZET

Products Affected

- NEXLIZET

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a cardiologist, endocrinologist, or a specialist in treatment of lipid disorders. |
| Coverage Duration | New starts will be authorized for 4 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For new starts ALL of the following must be provided: 1) Documentation of baseline low density lipoprotein cholesterol (LDL-C), 2) Member has tried and failed a high-intensity statin (i.e. atorvastatin 40-80 mg, rosuvastatin 20-40 mg) at maximum tolerated dose for 3 months via claim history or chart notes OR documentation has been provided that the member is not able to tolerate a statin, AND 3) Member will continue on maximum tolerated statin dose while receiving Nexlizet or documentation has been provided that the member is not able to tolerate a statin. In addition to the initial criteria above if the new start is for the diagnosis of hyperlipidemia and atherosclerotic cardiovascular disease (ASCVD), the following are required: 1) Documentation of history of least one of the following: myocardial infarction or acute coronary syndrome, stroke or transient ischemic attack, coronary artery disease with stable angina, coronary or other arterial revascularization, peripheral vascular disease, or aortic aneurysm, AND 2) Member must have a fasting LDL-C greater than or equal to 70 mg/dL. For continuation of therapy or reauthorization requests for all indications: 1) Documentation provided that the member has obtained clinical benefit from medication (e.g. LDL-C lowering from baseline), AND 2) Member will continue on maximum tolerated statin while receiving Nexlizet or documentation has been provided that the member is not able to tolerate a statin. |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------------------|
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

NITISINONE

Products Affected

- *nitisinone*
- ORFADIN ORAL CAPSULE 20 MG
- ORFADIN ORAL SUSPENSION

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a geneticist, metabolic specialist, hepatologist, or liver transplant specialist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

NITYR

Products Affected

- NITYR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a geneticist, metabolic specialist, hepatologist, or liver transplant specialist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

NON-AMPHETAMINE CENTRAL NERVOUS SYSTEM AGENTS

Products Affected

- *armodafinil*
- *modafinil*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

NOXAFIL

Products Affected

- NOXAFIL ORAL SUSPENSION
- *posaconazole*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Documentation of a consultation with an infectious disease specialist. |
| Coverage Duration | 28 days for oropharyngeal candidiasis, end of contract year for other indications |
| Other Criteria | For treatment of oropharyngeal candidiasis: trial of, contraindication to, or medical reason for not using fluconazole or itraconazole. For prophylaxis of invasive aspergillus infections due to being severely immunocompromised: trial of, contraindication to, or medical reason for not using voriconazole. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

NUCALA

Products Affected

- NUCALA

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | New starts will be approved for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | New starts for severe asthma: 1) blood eosinophil count greater than or equal to 150 cells per microliter within 6 weeks or 300 cells per microliter within 12 months, AND 2) symptoms with equal to or greater than 1 exacerbations in the previous 12 months requiring additional medical treatment, (e.g. oral systemic steroids) while on a high-dose inhaled corticosteroid with a long-acting B2 agonist. New starts for eosinophilic granulomatosis with polyangiitis (EGPA): trial of, contraindication to, or medical reason for not using one of the following medications: cyclophosphamide or methotrexate. New starts for hypereosinophilic syndrome without an identifiable non-hematologic secondary cause: 1) 2 or more flares within the past 12 months AND 2) trial of, contraindication to, or medical reason for not using oral corticosteroids. New starts for chronic rhinosinusitis with nasal polyps: trial of, contraindication to, or medical reason for not using nasal corticosteroids. Continuation of therapy or re-authorization for all indications: clinical benefit from use of the drug. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

NUEDEXTA

Products Affected

- NUEDEXTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Complete atrioventricular (AV) block without implanted pacemaker, or at high risk of complete AV block. History of heart failure. Concomitant use with MAOIs or use of MAOIs within 14 days. Concomitant use with drugs containing quinidine, quinine, or mefloquine. History of quinine-, mefloquine-, dextromethorphan/quinidine-, or quinidine-induced thrombocytopenia, hepatitis, bone marrow depression, or lupus-like syndrome. Non-Part D indications. |
| Required Medical Information | Confirmation diagnosis is for Part D indication. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

NUPLAZID

Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

NURTEC

Products Affected

- NURTEC

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist, headache specialist or pain specialist. |
| Coverage Duration | New starts will be approved for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For new starts for acute treatment of migraines: trial of, contraindication to, or medical reason for not using 2 triptans. For new starts for prevention of episodic migraine: trial of, contraindication to, or medical reason for not using Emgality or Aimovig. For continuation of therapy or reauthorization requests: documentation of improvement in pain and symptom(s) (e.g., photophobia, nausea, phonophobia). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

OCALIVA

Products Affected

- OCALIVA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Members with complete biliary obstruction. |
| Required Medical Information | For new starts: 1) Attestation that the member has failed at least a 12 month trial of ursodiol, or has a medical reason (e.g. intolerance, hypersensitivity) for being unable to tolerate ursodiol AND 2) lab results for baseline ALT/AST, alkaline phosphatase (ALP), and bilirubin within 90 days of request. For continuation of therapy or reauthorization: Documentation that that the member has responded to Ocaliva (e.g. improved biochemical markers (e.g., ALP, bilirubin, GGT, AST, ALT levels)). |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a gastroenterologist, hepatologist, or transplant specialist. |
| Coverage Duration | New starts will be authorized for 4 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

OFEV

Products Affected

- OFEV

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For a diagnosis of idiopathic pulmonary fibrosis: 1) Documentation of disease as demonstrated on a high resolution CT scan or through lung biopsy and 2) Documented trial of, contraindication to, or medical reason for not using Esbriet. For a diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD): documented trial of, contraindication to, or medical reason for not using mycophenolate mofetil or cyclophosphamide. For a diagnosis of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype: documentation is provided confirming diagnosis. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or lung transplant specialist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

OLUMIANT

Products Affected

- OLUMIANT ORAL TABLET 1 MG, 2 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For RA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following: Enbrel, Humira, Rinvoq, or Xeljanz, or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ORAL ANTINEOPLASTIC AGENTS

Products Affected

- *abiraterone acetate*
- ALECENSA
- ALUNBRIG
- AYVAKIT
- BALVERSA
- BOSULIF
- BRAFTOVI ORAL CAPSULE 75 MG
- BRUKINSA
- CABOMETYX
- CALQUENCE
- CAPRELSA
- COMETRIQ (100 MG DAILY DOSE)
ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE)
ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)
- COPIKTRA
- COTELLIC
- DAURISMO
- ERIVEDGE
- ERLEADA
- *erlotinib hcl*
- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *everolimus oral tablet soluble*
- EXKIVITY
- FOTIVDA
- GAVRETO
- GILOTRIF
- IBRANCE
- ICLUSIG
- IDHIFA
- *imatinib mesylate*
- IMBRUVICA
- INLYTA
- INQOVI
- INREBIC
- IRESSA
- JAKAFI
- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)
- KISQALI FEMARA(200 MG DOSE)
- KOSELUGO
- *lapatinib ditosylate*
- *lenalidomide*
- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)
- LONSURF
- LORBRENA
- LUMAKRAS
- LYNPARZA ORAL TABLET
- MEKINIST
- MEKTOVI
- NERLYNX
- NEXAVAR
- NINLARO
- NUBEQA
- ODOMZO
- ONUREG
- ORGOVYX
- PEMAZYRE
- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)
- POMALYST
- QINLOCK
- RETEVMO
- REVLIMID ORAL CAPSULE 2.5 MG,
20 MG
- ROZLYTREK
- RUBRACA
- RYDAPT
- SCEMBLIX
- *sorafenib tosylate*
- SPRYCEL

Formulary ID 22453

Last Updated: 07/2022

- STIVARGA
- *sunitinib malate*
- TABLOID
- TABRECTA
- TAFINLAR
- TAGRISSO
- TALZENNA ORAL CAPSULE 0.25 MG, 1 MG
- *talzenna oral capsule 0.5 mg, 0.75 mg*
- TASIGNA
- TAZVERIK
- TEPMETKO
- THALOMID
- TIBSOVO
- *toremifene citrate*
- *truseltiq (100mg daily dose)*
- *truseltiq (125mg daily dose)*
- *truseltiq (50mg daily dose)*
- *truseltiq (75mg daily dose)*
- TUKYSA
- TURALIO
- UKONIQ
- VENCLEXTA
- VENCLEXTA STARTING PACK
- VERZENIO
- VITRAKVI
- VIZIMPRO
- *vonjo*
- VOTRIENT
- *welireg*
- XALKORI
- XOSPATA
- XPOVIO (100 MG ONCE WEEKLY)
- XPOVIO (40 MG ONCE WEEKLY)
- XPOVIO (40 MG TWICE WEEKLY)
- XPOVIO (60 MG ONCE WEEKLY)
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY)
- XPOVIO (80 MG TWICE WEEKLY)
- XTANDI
- YONSA
- ZEJULA
- ZELBORAF
- ZOLINZA
- ZYDELIG
- ZYKADIA ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an oncologist or specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For new starts of Jakafi and Imbruvica for treatment of graft-versus-host disease (GVHD): documented trial of, contraindication to, or medical reason for not using a systemic corticosteroid. For continuation of therapy of Jakafi and Imbruvica for treatment of Graft-Versus-Host Disease (GVHD): documentation of clinical benefit from use of the drug (i.e. |

| PA Criteria | Criteria Details |
|-----------------------|--|
| | symptom improvement, reduction in corticosteroid dose). For Jakafi and Imbruvica for all other indications, approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ORAL ANTIPSYCHOTICS

Products Affected

- CAPLYTA
- FANAPT
- FANAPT TITRATION PACK
- VRAYLAR ORAL CAPSULE
- VRAYLAR ORAL CAPSULE THERAPY PACK

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For schizophrenia and manic or mixed episodes associated with bipolar I disorder: trial of, contraindication to, or medical reason for not using one formulary generic antipsychotic. For major depressive disorder associated with bipolar I or II disorder: trial of, contraindication to, or medical reason for not using two formulary generic antipsychotics. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ORENCIA

Products Affected

- ORENCIA CLICKJECT
- ORENCIA INTRAVENOUS
- ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For RA: Either 1) Trial of, medical reason for not using, or contraindication to 1 of the following: Enbrel or Humira or 2) If utilized within the past 120 days, approve for continuation of therapy. For pJIA: Either 1) Trial of, medical reason for not using, or contraindication to 1 of the following: Enbrel or Humira or 2) If utilized within the past 120 days, approve for continuation of therapy. For PsA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Cosentyx, Tremfya, Xeljanz, Rinvoq, Enbrel, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For acute graft versus host disease: attestation member is taking in combination with a calcineurin inhibitor and methotrexate. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ORILISSA

Products Affected

- ORILISSA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Patient has osteoporosis or severe hepatic impairment. |
| Required Medical Information | Trial of, contraindication to, or medical reason for not using the following concurrently for endometriosis: analgesic pain reliever (e.g. NSAIDs, COX-2 inhibitors) AND either combined estrogen-progestin oral contraceptive, progestin (e.g. medroxyprogesterone acetate, norethindrone), gonadotropin-releasing hormone (GnRH) agonists (e.g. Lupron Depot), OR danazol. For reauthorization, continued benefit with use of the drug. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an OB/GYN. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ORKAMBI

Products Affected

- ORKAMBI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Combination use with Kalydeco, Symdeko, or Trikafta. |
| Required Medical Information | Documentation of CFTR gene that is responsive to lumacaftor-ivacaftor treatment. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or an expert in the treatment of cystic fibrosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ORLADEYO

Products Affected

- ORLADEYO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an allergist, immunologist, rheumatologist or hematologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

OTEZLA

Products Affected

- OTEZLA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For PsA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Cosentyx, Tremfya, Xeljanz, Rinvoq, Enbrel, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For psoriasis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Cosentyx, Skyrizi, Tremfya, Enbrel, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

OXBRYTA

Products Affected

- OXBRYTA

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a hematologist. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | <p>New starts: Baseline labs have been submitted for the following: Hemoglobin (Hb), Indirect bilirubin, Reticulocytes. Documentation was provided that the member has had 1 or more pain crises in the last 12 months. Member has a baseline Hb level less than 10.5 g/dL. Documentation was provided that the member has been taking hydroxyurea at the maximum tolerated dose (or a medical reason was provided why the patient is unable to use hydroxyurea). For Oxbryta soluble tablets, medical reason for not using Oxbryta tablets. Continuation of therapy or reauthorization: Documentation submitted indicates clinical benefit at 6 months from initiation, and continued clinical benefit at subsequent 12-month intervals defined as the following: Documentation of one of the following: Hb increase from baseline (at 6 months from initiation) or maintenance of such Hb increase (at 12-month intervals thereafter) Or documentation of reduced number of vaso-occlusive/pain crises since Oxbryta was started Or documentation of one of the following: Decrease in indirect bilirubin from baseline Or decrease in percentage of reticulocytes from baseline.</p> |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

OXERVATE

Products Affected

- OXERVATE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an ophthalmologist. |
| Coverage Duration | Request will be authorized for 8 weeks. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

OXYCODONE ER

Products Affected

- *oxycodone hcl er oral tablet er 12 hour abuse-deterrent*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Members being treated for active cancer diagnoses, sickle cell diagnoses, those in hospice care, or receiving palliative care will be excluded from the concurrent benzodiazepine and muscle relaxant therapy requirement. For new starts, ALL of the following are required: (1) Member has documented history of receiving an immediate-release opioid, (2) Member has a documented trial of or intolerance to long-acting morphine sulfate, (3) If member is on concurrent benzodiazepines and/or muscle relaxant therapy, the prescriber attests that concurrent therapy is medically necessary, (4) Member is not being treated for substance abuse with buprenorphine-containing products. For continuing therapy, ALL of the following are required: (1) Member's pain has been assessed within the last 6 months, (2) Member has demonstrated clinical improvement in pain and function on current medication regimen, (3) If member is on concurrent benzodiazepines and/or muscle relaxant therapy, the prescriber attests that concurrent therapy is medically necessary, (4) Member is not being treated for substance abuse with buprenorphine-containing products. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

PALIPERIDONE

Products Affected

- *paliperidone er oral tablet extended release 24 hour 1.5 mg, 3 mg, 6 mg, 9 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For schizophrenia: trial of, contraindication to, or medical reason for not using an alternative generic formulary second generation atypical antipsychotic. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

PCSK9 INHIBITORS

Products Affected

- PRALUENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- REPATHA
- REPATHA PUSHTRONEX SYSTEM
- REPATHA SURECLICK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a cardiologist, endocrinologist, or a specialist in treatment of lipid disorders. |
| Coverage Duration | New starts will be authorized for 4 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For ALL diagnoses (including primary hyperlipidemia) for new starts: 1) documentation (copy of dated lab results required) of two fasting lipid panel reports within the past 12 months with abnormal LDL cholesterol results (above 70mg/dL) after treatment for a minimum of 3 months with two high potency statins (atorvastatin and rosuvastatin) or a medical reason (contraindication or intolerance) has been provided as to why the patient is unable to use these therapies, and 2) If patient experiences statin intolerance, trial of statin re-challenge with maximally tolerated dose of statins with continued abnormal LDL cholesterol results (above 70mg/dL) or with documented return of side effects. For familial hypercholesterolemia (FH), TWO of the following: 1) genetic testing (copy of dated lab results required) confirming FH diagnosis, 2) clinical manifestations of FH such as xanthomas or inflamed tendons, 3) a clinical diagnosis of FH using the Dutch Lipid Clinic Diagnostic criteria (total score greater than 8 points), OR Simon-Broome Diagnostic criteria (total cholesterol greater than 290 mg/dL or LDL-C greater than 190 mg/dL, plus tendon xanthoma in patient, first-degree parent, sibling or child) or second-degree relative (grandparent, uncle or aunt). For ASCVD, additional documentation has been provided that includes history of acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease |

| PA Criteria | Criteria Details |
|-----------------------|---|
| | presumed to be of atherosclerotic origin. For ALL diagnoses for continuation of therapy or reauthorization: repeat LDL cholesterol lab (copy of dated lab result required) showing improvement in LDL from new start. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

PEGINTERFERON

Products Affected

- PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML
- *pegasys subcutaneous solution prefilled syringe*

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For Hepatitis C: 1) Labs within 3 months of request: liver function tests and detectable HCV RNA viral load. 2) Documentation of genotype, treatment history, and if cirrhotic, documentation of compensated or decompensated cirrhosis. For Hepatitis B: 1) Labs within 3 months of request: ALT/AST, and 2) HBeAg status. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a gastroenterologist, hepatologist, infectious disease doctor or transplant specialist. |
| Coverage Duration | Request will be authorized for 24 to 48 weeks as defined by compendia. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

PENTAMIDINE SOLUTION FOR INJECTION

Products Affected

- *pentamidine isethionate injection*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

PERSERIS

Products Affected

- PERSERIS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | The member has a documented history of receiving oral risperidone without any clinically significant side effects. Additionally, the member has a documented trial and failure or medical reason (e.g. intolerance, hypersensitivity or contraindication) for not utilizing these therapies to manage their medical condition: Invega Sustenna, Invega Trinza or Risperdal Consta. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

PHENOXYBENZAMINE

Products Affected

- *phenoxybenzamine hcl oral*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Trial of, contraindication to, or medical reason for not using doxazosin. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

PRETOMANID

Products Affected

- *pretomanid*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | MDR-TB that is not treatment-intolerant or nonresponsive to standard therapy |
| Required Medical Information | Documentation of use in combination with bedaquiline and linezolid. Laboratory confirmed pulmonary MDR-TB resistant to isoniazid and rifampin |
| Age Restrictions | N/A |
| Prescriber Restrictions | Documentation of a consultation with an infectious disease specialist. |
| Coverage Duration | Request will be authorized for 26 weeks. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

PREVYMIS

Products Affected

- PREVYMIS ORAL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a hematologist, oncologist, infectious disease, or transplant specialist. |
| Coverage Duration | Request will be authorized for 6 months. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

PROLIA

Products Affected

- PROLIA SUBCUTANEOUS SOLUTION
PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For a diagnosis of osteoporosis: Documentation showing patient falls into one of the following categories: Postmenopausal woman or a male patient who has a bone mineral density (BMD) value consistent with osteoporosis (i.e., T-scores equal to or less than - 2.5) or who has had an osteoporotic fracture. Postmenopausal woman or man with a T-score between -1 and - 2.5 at the femoral neck or spine and a 10 year hip fracture probability greater than 3% or a 10 year major osteoporosis-related fracture probability greater than 20% based on the US-adapted WHO absolute fracture risk model. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | The following criteria is also applicable: trial of, contraindication to, or medical reason for not using an oral bisphosphonate. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

PROMACTA

Products Affected

- PROMACTA ORAL PACKET
- PROMACTA ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For chronic immune (idiopathic) thrombocytopenia (ITP): 1) Documented baseline platelet count less than 30,000 cells/ microL AND 2) Trial of, medical reason for not using, or contraindication to glucocorticosteroids. For severe aplastic anemia: 1) Prescribed with at least one formulary immunosuppressive agent OR trial of, contraindication to, or medical reason for not using one, AND 2) Documentation of baseline platelet count less than 20,000 cells/microL OR platelet count less than 30,000 cells/microL with bleeding OR reticulocyte count less than 20,000 cells/microL OR absolute neutrophil count less than 500 cells/microL. For thrombocytopenia in patients with Hepatitis C infection: documented baseline platelet count less than 50,000 cells/microL. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

PYRUKYND

Products Affected

- PYRUKYND
- PYRUKYND TAPER PACK

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts: 1) documentation of diagnosis and 2) baseline hemoglobin level. For continuation of therapy or reauthorization: documentation of clinical improvement (e.g. reduction in number of blood transfusions, or increase or stabilization in hemoglobin level). If the criteria are not met, may authorize up to 14 days of a Pyrukynd Taper Pack to allow for tapering. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a hematologist. |
| Coverage Duration | New starts: 6 mo. Cont of therapy or reauth: end of contract yr. Denial: 14 days for dose tapering. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

RAVICTI

Products Affected

- RAVICTI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Provider is a geneticist, metabolic specialist, gastroenterologist, hepatologist, or liver transplant specialist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

RECORLEV

Products Affected

- RECORLEV

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using ketoconazole tablets. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

REGRANEX

Products Affected

- REGRANEX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized for 20 weeks. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

RELISTOR

Products Affected

- RELISTOR ORAL
- RELISTOR SUBCUTANEOUS SOLUTION

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For appropriate indications, patient must have documented trial of or medical reason for not using the following: 1) lubiprostone, AND 2) lactulose. Additionally, for constipation caused by opioids that are used for chronic, non-cancer pain, patient must have a medical reason for not being able to use oral Relistor in order to receive Relistor injection. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

REXULTI

Products Affected

- REXULTI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For schizophrenia: trial of, contraindication to, or medical reason for not using one formulary generic antipsychotic. For major depressive disorder: trial of, contraindication to, or medical reason for not using two formulary generic antidepressants. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

REZUROCK

Products Affected

- REZUROCK

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a hematologist, oncologist, or other specialist in the treatment of hematopoietic cell transplants. |
| Coverage Duration | New starts: 3 months. Cont. of therapy or reauthorization: until end of contract year. |
| Other Criteria | For new starts: documented trial of, contraindication to, or medical reason for not using at least two lines of systemic immunosuppressive therapy (e.g. corticosteroids, tacrolimus, mycophenolate mofetil, Imbruvica, or Jakafi), one of which must be a systemic corticosteroid. For continuation of therapy or re-authorization: documentation of clinical benefit from use of the drug (i.e. symptom improvement, reduction in corticosteroid dose). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

RINVOQ

Products Affected

- RINVOQ ORAL TABLET EXTENDED RELEASE 24 HOUR 15 MG, 30 MG
- *rinvoq oral tablet extended release 24 hour 45 mg*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For RA: Trial of, medical reason for not using, or contraindication to 1 disease modifying antirheumatic drug (DMARD) (methotrexate, leflunomide, or sulfasalazine) and 1 tumor necrosis factor (TNF) blocker (Enbrel or Humira). For PsA: Trial of, medical reason for not using, or contraindication to 1 TNF blocker (Enbrel or Humira). For atopic dermatitis: trial of, contraindication to, or medical reason for not using: 1)topical tacrolimus or pimecrolimus and 2) Eucrisa. For UC: Trial of, medical reason for not using, or contraindication to 1 of the following conventional therapies: mercaptopurine, an aminosalicylate (i.e. mesalamine, sulfasalazine, azathioprine), or a corticosteroid (i.e. prednisone, methylprednisolone) and Humira. For ankylosing spondylitis: Trial of, medical reason for not using, or contraindication to naproxen and 1 TNF blocker (Enbrel or Humira). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

RYLAZE

Products Affected

- RYLAZE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an oncologist, hematologist, or specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

SAPROPTERIN

Products Affected

- *sapropterin dihydrochloride oral packet*
- *sapropterin dihydrochloride oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts: documentation of elevated baseline phenylalanine levels. Continuation of therapy or reauthorization: prescriber attests the member has improvement in phenylalanine levels from baseline. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | New starts will be authorized for 3 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

SECUADO

Products Affected

- SECUADO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Trial of, contraindication to, or medical reason for not using to one formulary generic antipsychotics. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

SEROSTIM

Products Affected

- SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a HIV specialist. |
| Coverage Duration | Request will be authorized for 12 weeks. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

SIGNIFOR

Products Affected

- SIGNIFOR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an endocrinologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

SILDENAFIL ORAL

Products Affected

- *sildenafil citrate oral suspension reconstituted*
- *sildenafil citrate oral tablet 20 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Documentation of concurrent nitrate or Adempas use. |
| Required Medical Information | Documentation of pulmonary arterial hypertension (PAH) WHO Group I and PAH Functional Class. Reviewer will verify available patient claim history to confirm patient is not using nitrates or Adempas. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or cardiologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For sildenafil suspension: Documentation of trial of, contraindication to, or medical reason for not using sildenafil tablet. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

SILIQ

Products Affected

- SILIQ

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For psoriasis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Cosentyx, Skyrizi, Tremfya, Enbrel, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

SIMPONI

Products Affected

- SIMPONI SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- SIMPONI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For RA: Either 1) Trial of, medical reason for not using, or contraindication to 1 of the following: Enbrel or Humira or 2) If utilized within the past 120 days, approve for continuation of therapy. For PsA: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Cosentyx, Tremfya, Xeljanz, Rinvoq, Enbrel, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For ankylosing spondylitis: Either 1) Trial of, medical reason for not using, or contraindication to 2 of the following therapies: Cosentyx, Enbrel, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For UC: Either 1) Trial of, medical reason for not using, or contraindication to Humira or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

SIRTURO

Products Affected

- SIRTURO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of prior trial of or medical reason for not using first-line TB regimen containing isoniazid and rifampin. Documentation (consistent with pharmacy claims data, OR for new members to the health plan consistent with medical chart history) that the member is currently taking 3 additional antimycobacterial drugs in combination to treat MDR-TB. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an infectious disease specialist. |
| Coverage Duration | Request will be authorized for 24 weeks. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

SKYRIZI

Products Affected

- SKYRIZI (150 MG DOSE)
- SKYRIZI PEN
- SKYRIZI SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For psoriasis: approve. For PsA: approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

SODIUM PHENYL BUTYRATE

Products Affected

- *sodium phenylbutyrate oral powder 3 gm/tsp*
- *sodium phenylbutyrate oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

SOFOSBUVIR/VELPATASVIR

Products Affected

- *sofosbuvir-velpatasvir*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Labs within 3 months of request: liver function tests and detectable HCV RNA viral load. In addition, documentation of genotype, treatment history, and if cirrhotic, documentation of compensated or decompensated cirrhosis. Prescriber attests to completing HBV screening and agrees to monitor for HBV reactivation if patient has a history of HBV infection. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a hepatologist, gastroenterologist, infectious disease specialist, or transplant specialist. |
| Coverage Duration | Request will be authorized for 12-24 weeks based on AASLD-IDSA guidelines |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

SOMAVERT

Products Affected

- SOMAVERT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

STELARA

Products Affected

- STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5ML
- STELARA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For PsA: Either 1) Trial of, medical reason for not using, or contraindication (e.g., safety concerns, not indicated for patients age) to 2 of the following therapies: Cosentyx, Tremfya, Xeljanz, Rinvoq, Enbrel, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For psoriasis: Either 1) Trial of, medical reason for not using, or contraindication (e.g., safety concerns, not indicated for patients age) to 2 of the following therapies: Cosentyx, Skyrizi, Tremfya, Enbrel, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For Crohns Disease: Either 1) Trial of, medical reason for not using, or contraindication (e.g., safety concerns, not indicated for patients age) to Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For UC: Either 1) Trial of, medical reason for not using, or contraindication (e.g., safety concerns, not indicated for patients age) to Humira or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

SUCRAID

Products Affected

- SUCRAID

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

SYMDEKO

Products Affected

- SYMDEKO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Combination use with Kalydeco, Orkambi, or Trikafta. |
| Required Medical Information | Documentation of CFTR gene that is responsive to tezacaftor-ivacaftor treatment. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or an expert in the treatment of cystic fibrosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

SYMLIN

Products Affected

- SYMLINPEN 120 SUBCUTANEOUS SOLUTION PEN-INJECTOR
- SYMLINPEN 60 SUBCUTANEOUS SOLUTION PEN-INJECTOR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Patient has confirmed gastroparesis. |
| Required Medical Information | For new starts: HbA1C values within 90 days of request is greater than or equal to 7% despite receiving insulin therapy. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not using two alternative formulary anti-diabetic agents. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

SYNAREL

Products Affected

- SYNAREL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

SYNDROS

Products Affected

- SYNDROS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not being able to use dronabinol capsules. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

SYNRIBO

Products Affected

- SYNRIBO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an oncologist or a hematologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

TADALAFIL

Products Affected

- *tadalafil (pah)*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Documentation of concurrent nitrate or Adempas use. |
| Required Medical Information | Documentation of pulmonary arterial hypertension (PAH) WHO Group I and PAH Functional Class. Reviewer will verify available patient claim history to confirm patient is not using nitrates or Adempas. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or cardiologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

TALTZ

Products Affected

- TALTZ

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For PsA: Either 1) Trial of, medical reason for not using, or contraindication (e.g., safety concerns, not indicated for patient's age) to 2 of the following therapies: Cosentyx, Tremfya, Xeljanz, Rinvoq, Enbrel, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For psoriasis: Either 1) Trial of, medical reason for not using, or contraindication (e.g., safety concerns, not indicated for patient's age) to 2 of the following therapies: Cosentyx, Skyrizi, Tremfya, Enbrel, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For ankylosing spondylitis: Either 1) Trial of, medical reason for not using, or contraindication (e.g., safety concerns, not indicated for patient's age) to 2 of the following therapies: Cosentyx, Enbrel, or Humira, or 2) If utilized within the past 120 days, approve for continuation of therapy. For non-radiographic axial spondyloarthritis: Either 1) Trial of, medical reason for not using, or contraindication (e.g., safety concerns, not indicated for patient's age) to Cosentyx, or 2) If utilized within the past 120 days, approve for continuation of therapy. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

TARPEYO

Products Affected

- TARPEYO

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts: attestation that member has 1) Diagnosis of primary immunoglobulin A nephropathy (IgAN) and 2) at risk of rapid disease progression. Member has an estimated glomerular filtration rate (eGFR) greater than or equal to 35 mL/min/1.73 m ² and proteinuria (defined as either greater than or equal to 1 g/day or urine protein/creatinine ratio [UPCR] greater than or equal to 1.5 g/g). For continuation of therapy: documentation that member has been on Tarpeyo for less than 9 months. For reauthorizations: Requests will not be allowed as the safety and efficacy of subsequent courses of Tarpeyo have not been established. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a nephrologist. |
| Coverage Duration | Request will be authorized for 9 months. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

TAVNEOS

Products Affected

- TAVNEOS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a rheumatologist or hematologist. |
| Coverage Duration | New starts will be authorized for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For new starts: 1) Prescriber attests that Tavneos will be prescribed in combination with corticosteroids AND cyclophosphamide unless there is documented trial of, contraindication to, or medical reason for not using these therapies. 2) Documentation of baseline Birmingham Vasculitis Activity Score (BVAS) score 3) Prescriber attestation that the patient will have liver function tests before treatment (ALT, AST, alkaline phosphate, and total bilirubin) and every 4 weeks after start of therapy for the first 6 months of treatment 4) Prescriber attestation that the patient has been screened for and does not have active hepatitis B virus (HBV) infection at baseline. For continuation of therapy or reauthorization: 1) Documentation of remission (BVAS score of 0) OR improvement in BVAS score 2) Prescriber attestation that patient has no abnormality in liver function tests (abnormality: ALT or AST greater than 3 times the upper limit of normal and bilirubin greater than 2 times the upper limit of normal) 3) Prescriber attestation that patient has no active HBV infection. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

TEFLARO

Products Affected

- TEFLARO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Documentation of a consultation with an infectious disease specialist. |
| Coverage Duration | Request will be authorized for 14 days. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

TERIPARATIDE

Products Affected

- *teriparatide (recombinant)*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation showing patient falls into one of the following categories: Postmenopausal woman who has a bone mineral density (BMD) value consistent with osteoporosis (i.e., T-scores equal to or less than -2.5) or postmenopausal woman who has had an osteoporotic fracture. Postmenopausal woman who has T-scores from -1.5 to -2.5 and at least one of the following risk factors for fracture: thinness [low body mass index (less than 21 kg/m ²)], history of fragility fracture since menopause, or history of hip fracture in a parent. Male greater than or equal to 65 years of age with T-score of -2.5 or less. Male less than 65 years of age with T-score of -2.5 or less and 2 or more risk factors for fractures or previous osteoporotic fracture. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | In addition, the following criteria is also applicable: 1) Trial of, medical reason for not using, or contraindication to an oral bisphosphonate and Prolia and 2) therapy does not exceed the therapy maximum of 2 years. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

THIOLA

Products Affected

- THIOLA EC
- *tiopronin oral*

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

TOLVAPTAN

Products Affected

- JYNARQUE
- *tolvaptan*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concomitant use with strong CYP3A4 inhibitors (i.e. clarithromycin, ketoconazole, itraconazole, ritonavir, lopinavir-ritonavir, indinavir-ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, conivaptan, and telithromycin). |
| Required Medical Information | Reviewer will verify available patient claim history to confirm patient is not using a strong CYP3A4 inhibitor (i.e. clarithromycin, ketoconazole, itraconazole, ritonavir, lopinavir-ritonavir, indinavir-ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, conivaptan, and telithromycin). |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a cardiologist, endocrinologist, hepatologist, or nephrologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

TOPICAL ANTINEOPLASTIC RETINOIDS

Products Affected

- *bexarotene external*
- *panretin*
- TARGRETIN EXTERNAL

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

TOPICAL TESTOSTERONE

Products Affected

- testosterone transdermal gel 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)*
- testosterone transdermal solution*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Patient initiating topical testosterone therapy for hypogonadism must have both of the following characteristics of hypogonadism: 1) symptoms associated with hypogonadism (e.g. unexplained mild anemia, low libido, decreased energy, etc.) 2) Two instances of low serum total or free testosterone, as defined by the reference range by the lab. For all patients, provider attests that PSA levels, hemoglobin, hematocrit and testosterone levels will be monitored periodically throughout the treatment as indicated in compendia. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

TRANSDERMAL LIDOCAINE

Products Affected

- *lidocaine external patch 5 %*
- ZTLIDO

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

TREMFYA

Products Affected

- TREMFYA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For PsA or psoriasis: approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

TRIENTINE

Products Affected

- *trientine hcl*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Trial of, contraindication to, or medical reason for not using penicillamine. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

TRIKAFTA

Products Affected

- TRIKAFTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Combination use with Kalydeco, Orkambi, or Symdeko. |
| Required Medical Information | Documentation of CFTR gene that is responsive to elexacaftor-tezacaftor-ivacaftor treatment. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or an expert in the treatment of cystic fibrosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

TYMLOS

Products Affected

- TYMLOS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation showing patient falls into one of the following categories: Postmenopausal woman who has a bone mineral density (BMD) value consistent with osteoporosis (i.e., T-scores equal to or less than -2.5) or postmenopausal woman who has had an osteoporotic fracture. Postmenopausal woman who has T-scores from -1.5 to -2.5 and at least one of the following risk factors for fracture: thinness [low body mass index (less than 21 kg/m ²)], history of fragility fracture since menopause, or history of hip fracture in a parent. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | The following criteria is also applicable: 1) trial of, contraindication to, or medical reason for not using an oral bisphosphonate and Prolia, and 2) therapy does not exceed 2 years. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

UBRELVY

Products Affected

- UBRELVY

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist, headache specialist or pain specialist. |
| Coverage Duration | New starts will be approved for 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | For new starts: trial of, contraindication to, or medical reason for not using 2 triptans. For continuation of therapy or reauthorization requests: documentation of improvement in pain and symptom(s) (e.g., photophobia, nausea, phonophobia). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

UPTRAVI

Products Affected

- UPTRAVI ORAL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of pulmonary arterial hypertension (PAH) WHO Group I and PAH Functional Class. Trial of, contraindication to, or medical reason for not using a formulary phosphodiesterase inhibitor in combination with a formulary endothelin receptor antagonist. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or cardiologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

VALCHLOR

Products Affected

- VALCHLOR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with an oncologist or dermatologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | Trial of, contraindication to, or medical reason for not being able to use one of the following: a topical corticosteroids or a topical retinoids. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

VASCEPA

Products Affected

- *icosapent ethyl*
- VASCEPA ORAL CAPSULE 0.5 GM

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For a diagnosis of hypertriglyceridemia: Documented trial of, contraindication to, or medical reason for not using statins at maximum tolerated dose OR documented statin intolerance AND omega-3-acid ethyl esters capsule. For a diagnosis of cardiovascular risk reduction, ALL the following are required: 1) Documentation of hypertriglyceridemia greater than or equal to 150 mg/dL: 2) Documented trial of, contraindication to, or medical reason for not using statins at maximum tolerated dose for 3 months OR documented statin intolerance AND 3) Documentation of one of the following: Established atherosclerotic cardiovascular disease (e.g., coronary artery disease, cerebrovascular accident, carotid disease, peripheral artery disease) OR age greater than or equal to 50 years old with established diabetes and at least one additional risk factor for cardiovascular disease (e.g., hypertension, renal dysfunction, retinopathy, albuminuria, males age greater than or equal to 55 years old or females age greater than or equal to 65 years old). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

VENTAVIS

Products Affected

- VENTAVIS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Documentation of pulmonary arterial hypertension (PAH) WHO Group I classification and PAH Functional Class. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist or cardiologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

VIGABATRIN

Products Affected

- *vigabatrin*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For infantile spasms or West syndrome, the request will be approved. Patient must have a diagnosis of refractory complex partial seizures who is currently receiving another antiepileptic drug and the patient has experienced treatment failure from two generic alternative formulary antiepileptic agents. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

VMAT-2 INHIBITORS

Products Affected

- AUSTEDO
- INGREZZA ORAL CAPSULE 40 MG, 80 MG
- *ingrezza oral capsule 60 mg*
- INGREZZA ORAL CAPSULE THERAPY PACK
- *tetrabenazine*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | If the request is for tetrabenazine, request will be approved. For Ingrezza, trial of or medical reason for not using the tetrabenazine for tardive dyskinesia. For Austedo, trial of or medical reason for not using the following if applicable for submitted diagnosis 1) Chorea associated with Huntington disease- trial of tetrabenazine. 2) Tardive dyskinesia -trial of tetrabenazine and Ingrezza. Reauthorization: Confirmation of improvement in tardive dyskinesia symptoms or chorea associated with Huntington disease symptoms. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a neurologist, clinical geneticist, or psychiatrist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

VORICONAZOLE

Products Affected

- *voriconazole intravenous*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Non-Part D indications. |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

VOSEVI

Products Affected

- VOSEVI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | Labs within 3 months of request: liver function tests and detectable HCV RNA viral load. In addition, documentation of genotype, treatment history, and if cirrhotic, documentation of compensated or decompensated cirrhosis. Prescriber attests to completing HBV screening and agrees to monitor for HBV reactivation if patient has a history of HBV infection. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a hepatologist, gastroenterologist, infectious disease specialist, or transplant specialist. |
| Coverage Duration | Request will be authorized for 12 weeks as per AASLD-IDSA guidance. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

WHITE BLOOD CELL STIMULATORS

Products Affected

- FULPHILA
- GRANIX
- LEUKINE INJECTION SOLUTION RECONSTITUTED
- NEULASTA ONPRO
- NEULASTA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- NEUPOGEN INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6ML
- NEUPOGEN INJECTION SOLUTION PREFILLED SYRINGE
- NIVESTYM INJECTION SOLUTION PREFILLED SYRINGE
- NYVEPRIA
- UDENYCA
- ZARXIO
- ZIEXTENZO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For new starts for Neupogen and Granix: documentation of trial of, contraindication to, or medical reason for not using Zarxio and Nivestym. For new starts for Neulasta, Fulphila, and Nyvepria: documentation of trial of, contraindication to, or medical reason for not using Udenyca and Ziextenzo. Continuation of therapy or re-authorization criteria: diagnosis of chronic neutropenia or a medical reason for continued need for GCSF. |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | For new starts: 4 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

XATMEP

Products Affected

- XATMEP

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an oncologist or rheumatologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

XELJANZ

Products Affected

- XELJANZ
- XELJANZ XR

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Specialist for submitted diagnosis. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For RA: Trial of, medical reason for not using, or contraindication to 1 disease modifying antirheumatic drug (DMARD) (methotrexate, leflunomide, or sulfasalazine) and 1 tumor necrosis factor (TNF) blocker (Enbrel or Humira). For pJIA: Trial of, medical reason for not using, or contraindication to 1 of the following DMARDs: methotrexate or leflunomide and 1 TNF blocker (Enbrel or Humira). For PsA: Trial of, medical reason for not using, or contraindication to 1 TNF blocker (Enbrel or Humira). For UC: Trial of, medical reason for not using, or contraindication to 1 of the following conventional therapies: mercaptopurine, an aminosalicylate (i.e. mesalamine, sulfasalazine, azathioprine), or a corticosteroid (i.e. prednisone, methylprednisolone) and 1 TNF blocker (Enbrel or Humira). |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

XERMELO

Products Affected

- XERMELO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

XGEVA

Products Affected

- XGEVA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Patients with baseline hypocalcemia |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | New starts: Serum calcium levels. Reauthorization criteria for malignant hypercalcemia: albumin-adjusted serum calcium level below 12.5mg/dl within 30 days of request. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

XIFAXAN

Products Affected

- XIFAXAN

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | For diagnosis of hepatic encephalopathy (HE): trial of, contraindication to, or medical reason for not using lactulose. For diagnosis of irritable bowel syndrome with diarrhea (IBSD): 1) trial of, contraindication to, or medical reason for not using loperamide and dicyclomine AND 2) no more than 3 courses of 14 days each. For travelers diarrhea (TD) caused by noninvasive strains of E. Coli (with no bloody stools or fever): patient must be intolerant to or must have had a trial of at least 3 days of one of the following agents: ciprofloxacin, ofloxacin, levofloxacin or azithromycin. |
| Age Restrictions | N/A |
| Prescriber Restrictions | For HE: gastroenterologist or hepatologist. For IBS-D: gastroenterologist. |
| Coverage Duration | For HE: contract year. For IBSD: 14 days (cannot exceed 3 courses of 14 days each). For TD: 3 days. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

XOLAIR

Products Affected

- XOLAIR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a pulmonologist, allergist, immunologist, dermatologist, or otolaryngologist. |
| Coverage Duration | New Starts: 6 months. Cont of therapy or reauth until end of contract year. |
| Other Criteria | <p>New starts for moderate to severe persistent allergic asthma: 1) Evidence of specific allergic sensitivity confirmed by positive skin test (i.e. prick/puncture test) or blood test (i.e. radioallergosorbent test) for a specific IgE or in vitro reactivity to a perennial aeroallergen, AND 2) Pretreatment serum IgE levels greater than 30 IU/mL, AND 3) Symptoms are not adequately controlled with high-dose inhaled corticosteroid (ICS) plus long-acting beta2-agonist (LABA) for at least 3 months, or there is a medical reason for not using these drugs. Continuation of therapy or reauthorization criteria for moderate to severe persistent allergic asthma: 1) Reduction in asthma exacerbation resulting in systemic steroid use and/or hospitalization, OR 2) Reduction of rescue inhaler use, OR 3) Documentation of improvement in pulmonary function tests since baseline (prior to initiation of Xolair). New starts for chronic idiopathic urticaria: 1) inadequate symptomatic relief despite trial of two weeks of two different oral antihistamine therapies (unless contraindicated), AND 2) disease must be severe enough to warrant short term systemic corticosteroid therapy for management of urticaria. Continuation of therapy or reauthorization criteria for chronic idiopathic urticaria: 1) improvement from baseline of symptoms associated with urticaria within 6 months of Xolair use. New starts for c: 1) currently using an intranasal corticosteroid, will be prescribed an intranasal corticosteroid with request, or has a medical reason for not using an intranasal corticosteroid. Continuation of therapy or</p> |

| PA Criteria | Criteria Details |
|-----------------------|---|
| | reauthorization criteria for nasal polyps: 1) Documentation has been provided that demonstrates a clinical benefit (e.g. improvements in symptom severity, nasal polyp score [NPS], sino-nasal outcome test-22 [SNOT-22], nasal congestion score [NCS]) AND 2) continued use of intranasal corticosteroid, or has a medical reason for not using one. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

XURIDEN

Products Affected

- XURIDEN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be an endocrinologist, metabolic specialist, clinical geneticist or hematologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

XYREM

Products Affected

- XYREM

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a sleep specialist, pulmonologist, or neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For somnolence associated with narcolepsy: trial of, contraindication to, or medical reason for not using an approved formulary CNS stimulant (e.g. methylphenidate, modafinil, armodafinil, etc.). For cataplexy associated with narcolepsy, approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

XYWAV

Products Affected

- XYWAV

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescriber must be a sleep specialist or a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | For treatment of somnolence associated with narcolepsy, patient must have documentation of either trial of or a medical reason for being unable to use an approved formulary CNS stimulant (e.g. methylphenidate, modafinil, armodafinil, etc.). For the treatment of cataplexy associated with narcolepsy or idiopathic hypersomnia, approve. |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ZTALMY

Products Affected

- ZTALMY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | N/A |
| Required Medical Information | N/A |
| Age Restrictions | N/A |
| Prescriber Restrictions | Prescribed by or in consultation with a neurologist. |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

ZYPREXA RELPREVV

Products Affected

- ZYPREXA RELPREVV RECONSTITUTED 210 MG, 300 MG,
INTRAMUSCULAR SUSPENSION 405 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | N/A |
| Required Medical Information | The member has taken oral olanzapine without significant side effects. Trial of, contraindication to, or medical reason for not using Invega Sustenna, Invega Trinza or Risperdal Consta. |
| Age Restrictions | N/A |
| Prescriber Restrictions | N/A |
| Coverage Duration | Request will be authorized until the end of the contract year. |
| Other Criteria | N/A |
| Indications | All Medically-accepted Indications. |
| Off-Label Uses | N/A |

PART B VERSUS PART D

Products Affected

- ABELCET INTRAVENOUS SUSPENSION 5 MG/ML
- *acetylcysteine inhalation solution 10 %, 20 %*
- *acyclovir sodium intravenous solution 50 mg/ml*
- *albuterol sulfate inhalation nebulization solution (2.5 mg/3ml) 0.083%, (5 mg/ml) 0.5%, 0.63 mg/3ml, 1.25 mg/3ml, 2.5 mg/0.5ml*
- AMBISOME INTRAVENOUS SUSPENSION RECONSTITUTED 50 MG
- AMINOSYN II INTRAVENOUS SOLUTION 15 %
- AMINOSYN-PF 7% INTRAVENOUS SOLUTION 7 %
- AMINOSYN-PF INTRAVENOUS SOLUTION 7 %
- *amphotericin b intravenous solution reconstituted 50 mg*
- *amphotericin b liposome intravenous suspension reconstituted 50 mg*
- *aprepitant oral 80 & 125 mg*
- *aprepitant oral capsule 125 mg, 40 mg, 80 & 125 mg, 80 mg*
- ASTAGRAF XL ORAL CAPSULE EXTENDED RELEASE 24 HOUR 0.5 MG, 1 MG, 5 MG
- *azathioprine oral tablet 50 mg*
- *budesonide inhalation suspension 0.25 mg/2ml, 0.5 mg/2ml, 1 mg/2ml*
- CLINIMIX/DEXTROSE (4.25/10) INTRAVENOUS SOLUTION 4.25 %
- CLINISOL SF INTRAVENOUS SOLUTION 15 %
- *cromolyn sodium inhalation nebulization solution 20 mg/2ml*
- *cyclophosphamide oral capsule 25 mg, 50 mg*
- *cyclophosphamide oral tablet 25 mg, 50 mg*
- *cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg*
- *cyclosporine modified oral solution 100 mg/ml*
- *cyclosporine oral capsule 100 mg, 25 mg*
- *dexamethasone sodium phosphate injection solution 120 mg/30ml, 20 mg/5ml, 4 mg/ml*
- *diphtheria-tetanus toxoids dt intramuscular suspension 25-5 lfu/0.5ml*
- *dronabinol oral capsule 10 mg, 2.5 mg, 5 mg*
- EMEND ORAL SUSPENSION RECONSTITUTED 125 MG/5ML
- ENGERIX-B INJECTION SUSPENSION 10 MCG/0.5ML, 20 MCG/ML
- ENVARUS XR ORAL TABLET EXTENDED RELEASE 24 HOUR 0.75 MG, 1 MG, 4 MG
- *everolimus oral tablet 0.25 mg, 0.5 mg, 0.75 mg, 1 mg*
- FLEBOGAMMA DIF INTRAVENOUS SOLUTION 5 GM/50ML
- GAMMAGARD INJECTION SOLUTION 1 GM/10ML, 10 GM/100ML, 2.5 GM/25ML, 20 GM/200ML, 30 GM/300ML, 5 GM/50ML
- GAMMAGARD S/D LESS IGA INTRAVENOUS SOLUTION RECONSTITUTED 10 GM, 5 GM
- GAMMAKED INJECTION SOLUTION 1 GM/10ML
- GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 5 GM/50ML
- GAMUNEX-C INJECTION SOLUTION 1 GM/10ML
- GENGRAF ORAL CAPSULE 100 MG, 25 MG
- GENGRAF ORAL SOLUTION 100 MG/ML
- *granisetron hcl oral tablet 1 mg*

- *heparin sodium (porcine) injection solution 1000 unit/ml, 10000 unit/ml, 5000 unit/ml*
- HEPLISAV-B INTRAMUSCULAR SOLUTION PREFILLED SYRINGE 20 MCG/0.5ML
- IMOVAX RABIES INTRAMUSCULAR INJECTABLE 2.5 UNIT/ML
- INTRALIPID INTRAVENOUS EMULSION 20 %, 30 %
- *ipratropium bromide inhalation solution 0.02 %*
- *ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml*
- *levalbuterol hcl inhalation nebulization solution 0.31 mg/3ml, 0.63 mg/3ml, 1.25 mg/3ml*
- *mycophenolate mofetil oral capsule 250 mg*
- *mycophenolate mofetil oral suspension reconstituted 200 mg/ml*
- *mycophenolate mofetil oral tablet 500 mg*
- *mycophenolate sodium oral tablet delayed release 180 mg, 360 mg*
- *nalbuphine hcl injection solution 10 mg/ml*
- NULOJIX INTRAVENOUS SOLUTION RECONSTITUTED 250 MG
- NUTRILIPID INTRAVENOUS EMULSION 20 %
- *ondansetron hcl oral solution 4 mg/5ml*
- *ondansetron hcl oral tablet 24 mg, 4 mg, 8 mg*
- *ondansetron oral tablet dispersible 4 mg, 8 mg*
- *pentamidine isethionate inhalation solution reconstituted 300 mg*
- PERFORMIST INHALATION NEBULIZATION SOLUTION 20 MCG/2ML
- PLENAMINE INTRAVENOUS SOLUTION 15 %
- *prehevbrio intramuscular suspension 10 mcg/ml*
- PRIVIGEN INTRAVENOUS SOLUTION 10 GM/100ML, 20 GM/200ML, 40 GM/400ML, 5 GM/50ML
- PROGRAF INTRAVENOUS SOLUTION 5 MG/ML
- PROGRAF ORAL PACKET 0.2 MG, 1 MG
- *pulmozyme inhalation solution 2.5 mg/2.5ml*
- RABAVERT INTRAMUSCULAR SUSPENSION RECONSTITUTED
- RECOMBIVAX HB INJECTION SUSPENSION 10 MCG/ML, 10 MCG/ML (1ML SYRINGE), 40 MCG/ML, 5 MCG/0.5ML
- SANDIMMUNE ORAL SOLUTION 100 MG/ML
- *sirolimus oral solution 1 mg/ml*
- *sirolimus oral tablet 0.5 mg, 1 mg, 2 mg*
- *tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg*
- TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF/0.5ML
- *tetanus-diphtheria toxoids td intramuscular suspension 2-2 lf/0.5ml*
- *tobramycin inhalation nebulization solution 300 mg/5ml*
- *ziprasidone mesylate intramuscular solution reconstituted 20 mg*

Details

This drug may be covered under Medicare Part B or D depending upon the circumstances. Information may need to be submitted describing the use and setting of the drug to make the determination.

Index

A

| | |
|---|---------------|
| ABELCET INTRAVENOUS | |
| SUSPENSION 5 MG/ML..... | 200 |
| ABILIFY MAINTENA | |
| INTRAMUSCULAR PREFILLED | |
| SYRINGE | 10 |
| ABILIFY MAINTENA | |
| INTRAMUSCULAR SUSPENSION | |
| RECONSTITUTED ER..... | 10 |
| abiraterone acetate | 112, 113, 114 |
| acetylcysteine inhalation solution 10 %, 20 | |
| % | 200 |
| acitretin | 1 |
| ACTEMRA ACTPEN | 2 |
| ACTEMRA SUBCUTANEOUS | 2 |
| ACTHAR | 59 |
| ACTIMMUNE..... | 3 |
| acyclovir sodium intravenous solution 50 | |
| mg/ml | 200 |
| adefovir dipivoxil..... | 4 |
| ADEMPAS | 5 |
| AIMOVIG..... | 21 |
| albuterol sulfate inhalation nebulization | |
| solution (2.5 mg/3ml) 0.083%, (5 mg/ml) | |
| 0.5%, 0.63 mg/3ml, 1.25 mg/3ml, 2.5 | |
| mg/0.5ml | 200 |
| ALECENSA..... | 112, 113, 114 |
| ALUNBRIG..... | 112, 113, 114 |
| AMBISOME INTRAVENOUS | |
| SUSPENSION RECONSTITUTED 50 | |
| MG | 200 |
| ambrisentan | 7 |
| AMINOSYN II INTRAVENOUS | |
| SOLUTION 15 % | 200 |
| AMINOSYN-PF 7% INTRAVENOUS | |
| SOLUTION 7 % | 200 |
| AMINOSYN-PF INTRAVENOUS | |
| SOLUTION 7 % | 200 |
| amitriptyline hcl oral..... | 64 |
| amoxapine | 64 |
| amphotericin b intravenous solution | |
| reconstituted 50 mg..... | 200 |

| | |
|---|---------------|
| amphotericin b liposome intravenous | |
| suspension reconstituted 50 mg | 200 |
| apomorphine hcl subcutaneous | 8 |
| aprepitant oral 80 & 125 mg | 200 |
| aprepitant oral capsule 125 mg, 40 mg, 80 & | |
| 125 mg, 80 mg | 200 |
| ARALAST NP INTRAVENOUS | |
| SOLUTION RECONSTITUTED 1000 | |
| MG, 500 MG..... | 6 |
| ARANESP (ALBUMIN FREE) | |
| INJECTION SOLUTION 100 MCG/ML, | |
| 200 MCG/ML, 25 MCG/ML, 40 | |
| MCG/ML, 60 MCG/ML | 45 |
| ARANESP (ALBUMIN FREE) | |
| INJECTION SOLUTION PREFILLED | |
| SYRINGE | 45 |
| ARCALYST | 9 |
| ARISTADA INITIO | 10 |
| ARISTADA INTRAMUSCULAR | |
| PREFILLED SYRINGE 1064 | |
| MG/3.9ML, 441 MG/1.6ML, 662 | |
| MG/2.4ML, 882 MG/3.2ML | 10 |
| armodafinil..... | 103 |
| ASCOMP-CODEINE | 65 |
| ASTAGRAF XL ORAL CAPSULE | |
| EXTENDED RELEASE 24 HOUR 0.5 | |
| MG, 1 MG, 5 MG | 200 |
| AUBAGIO | 93 |
| AUSTEDO..... | 184 |
| AYVAKIT | 112, 113, 114 |
| azathioprine oral tablet 50 mg..... | 200 |
| B | |
| BAC | 65 |
| BAFIERTAM | 93 |
| BALVERSA | 112, 113, 114 |
| BENLYSTA SUBCUTANEOUS..... | 12 |
| benznidazole | 13 |
| BESREMI | 14 |
| BETASERON SUBCUTANEOUS KIT .. | 93 |
| bexarotene external | 171 |
| bosentan | 15 |
| BOSULIF..... | 112, 113, 114 |

BRAFTOVI ORAL CAPSULE 75 MG 112, 113, 114
BRUKINSA 112, 113, 114
budesonide er oral tablet extended release 24 hour 16
budesonide inhalation suspension 0.25 mg/2ml, 0.5 mg/2ml, 1 mg/2ml 200
butalbital-acetaminophen oral tablet 50-325 mg 65
butalbital-apap-caff-cod oral capsule 50-325-40-30 mg 65
butalbital-apap-caffeine oral capsule 50-325-40 mg 65
butalbital-apap-caffeine oral tablet 50-325-40 mg 65
butalbital-asa-caff-codeine..... 65
butalbital-asa-caffeine..... 65
butalbital-aspirin-caffeine oral capsule..... 65

C
CABOMETYX 112, 113, 114
CALQUENCE 112, 113, 114
CAMCEVI 56
CAPLYTA 115
CAPRELSA 112, 113, 114
carglumic acid oral tablet soluble 18
carisoprodol oral 67
carisoprodol-aspirin-codeine..... 67
casprofungin acetate..... 19
CERDELGA 20
chlorzoxazone oral tablet 500 mg 67
CHOLBAM..... 22
CIBINQO..... 23
CIMZIA PREFILLED SUBCUTANEOUS PREFILLED SYRINGE KIT 24, 25
CIMZIA STARTER KIT SUBCUTANEOUS PREFILLED SYRINGE KIT..... 24, 25
CIMZIA SUBCUTANEOUS KIT 2 X 200 MG 24, 25
CINRYZE 17
clemastine fumarate oral tablet 2.68 mg .. 62, 63
CLINIMIX/DEXTROSE (4.25/10) INTRAVENOUS SOLUTION 4.25 % 200
CLINISOL SF INTRAVENOUS SOLUTION 15 % 200

clobazam oral suspension 26
clobazam oral tablet 26
clomipramine hcl oral 64
COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG 112, 113, 114
COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG 112, 113, 114
COMETRIQ (60 MG DAILY DOSE)... 112, 113, 114
COPIKTRA..... 112, 113, 114
CORLANOR..... 27
CORTROPHIN 28
COSENTYX (300 MG DOSE)..... 29
COSENTYX SENSOREADY (300 MG). 29
COSENTYX SENSOREADY PEN 29
COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 150 MG/ML..... 29
cosentyx subcutaneous solution prefilled syringe 75 mg/0.5ml 29
COTELLIC 112, 113, 114
cromolyn sodium inhalation nebulization solution 20 mg/2ml 200
cyclobenzaprine hcl oral tablet 10 mg, 5 mg 67
cyclophosphamide oral capsule 25 mg, 50 mg 200
cyclophosphamide oral tablet 25 mg, 50 mg 200
cyclosporine modified oral capsule 100 mg, 25 mg, 50 mg 200
cyclosporine modified oral solution 100 mg/ml 200
cyclosporine oral capsule 100 mg, 25 mg 200
cyproheptadine hcl oral..... 62, 63
CYSTAGON..... 30

D
dalfampridine er 31
DAURISMO 112, 113, 114
deferasirox..... 32
deferasirox granules 32
deferiprone 51
dexamethasone sodium phosphate injection solution 120 mg/30ml, 20 mg/5ml, 4 mg/ml 200

| | | | |
|---|--------|--|---------------|
| DIACOMIT..... | 34 | UNIT/ML, 3000 UNIT/ML, 4000 | |
| DIFICID..... | 35 | UNIT/ML..... | 45 |
| DIGITEK ORAL TABLET 250 MCG..... | 66 | EPRONTIA..... | 44 |
| DIGOX ORAL TABLET 250 MCG..... | 66 | ergoloid mesylates oral..... | 62, 63 |
| digoxin oral solution..... | 66 | ERIVEDGE..... | 112, 113, 114 |
| digoxin oral tablet 250 mcg..... | 66 | ERLEADA..... | 112, 113, 114 |
| dimethyl fumarate oral..... | 93 | erlotinib hcl..... | 112, 113, 114 |
| dimethyl fumarate starter pack..... | 93 | ESBRIET..... | 46 |
| diphtheria-tetanus toxoids dt intramuscular | | eszopiclone..... | 68 |
| suspension 25-5 lfu/0.5ml..... | 200 | EUCRISA..... | 47 |
| dipyridamole oral..... | 62, 63 | everolimus oral tablet 0.25 mg, 0.5 mg, 0.75 | |
| disopyramide phosphate oral..... | 62, 63 | mg, 1 mg..... | 200 |
| DOPTELET..... | 36 | everolimus oral tablet 10 mg, 2.5 mg, 5 mg, | |
| doxepin hcl external..... | 37 | 7.5 mg..... | 112, 113, 114 |
| doxepin hcl oral capsule..... | 64 | everolimus oral tablet soluble..... | 112, 113, 114 |
| doxepin hcl oral concentrate..... | 64 | EVRYSDI..... | 48 |
| dronabinol oral capsule 10 mg, 2.5 mg, 5 mg | | EXKIVITY..... | 112, 113, 114 |
| | 200 | EXTAVIA SUBCUTANEOUS KIT..... | 93 |
| DUPIXENT..... | 38 | F | |
| E | | FANAPT..... | 115 |
| EGRIFTA SV..... | 39 | FANAPT TITRATION PACK..... | 115 |
| ELIGARD..... | 56 | FASENRA..... | 49 |
| EMEND ORAL SUSPENSION | | FASENRA PEN..... | 49 |
| RECONSTITUTED 125 MG/5ML.... | 200 | fentanyl citrate buccal lozenge on a handle | |
| EMGALITY..... | 21 | | 50 |
| EMGALITY (300 MG DOSE)..... | 21 | fentanyl transdermal patch 72 hour 100 | |
| EMPAVELI..... | 40 | mcg/hr..... | 61 |
| ENBREL MINI..... | 41 | FINTEPLA..... | 52 |
| ENBREL SUBCUTANEOUS SOLUTION | | FIRDAPSE..... | 53 |
| 25 MG/0.5ML..... | 41 | FIRMAGON (240 MG DOSE)..... | 56 |
| ENBREL SUBCUTANEOUS SOLUTION | | FIRMAGON SUBCUTANEOUS | |
| REFILLED SYRINGE..... | 41 | SOLUTION RECONSTITUTED 80 MG | |
| ENBREL SUBCUTANEOUS SOLUTION | | | 56 |
| RECONSTITUTED..... | 41 | FLEBOGAMMA DIF INTRAVENOUS | |
| ENBREL SURECLICK SUBCUTANEOUS | | SOLUTION 5 GM/50ML..... | 200 |
| SOLUTION AUTO-INJECTOR..... | 41 | FOTIVDA..... | 112, 113, 114 |
| ENDARI..... | 42 | FULPHILA..... | 187 |
| ENGERIX-B INJECTION SUSPENSION | | G | |
| 10 MCG/0.5ML, 20 MCG/ML..... | 200 | GALAFOLD..... | 54 |
| ENVARUSUS XR ORAL TABLET | | GAMMAGARD INJECTION SOLUTION | |
| EXTENDED RELEASE 24 HOUR 0.75 | | 1 GM/10ML, 10 GM/100ML, 2.5 | |
| MG, 1 MG, 4 MG..... | 200 | GM/25ML, 20 GM/200ML, 30 | |
| EPIDIOLEX..... | 43 | GM/300ML, 5 GM/50ML..... | 200 |
| EPOGEN INJECTION SOLUTION 10000 | | GAMMAGARD S/D LESS IGA | |
| UNIT/ML, 2000 UNIT/ML, 20000 | | INTRAVENOUS SOLUTION | |
| | | RECONSTITUTED 10 GM, 5 GM.... | 200 |

GAMMAKED INJECTION SOLUTION 1
GM/10ML 200

GAMMAPLEX INTRAVENOUS
SOLUTION 10 GM/100ML, 10
GM/200ML, 20 GM/200ML, 5
GM/50ML 200

GAMUNEX-C INJECTION SOLUTION 1
GM/10ML 200

GATTEX..... 55

GAVRETO 112, 113, 114

GENGRAF ORAL CAPSULE 100 MG, 25
MG 200

GENGRAF ORAL SOLUTION 100
MG/ML 200

GENOTROPIN MINIQUICK
SUBCUTANEOUS PREFILLED
SYRINGE 58

GENOTROPIN SUBCUTANEOUS
CARTRIDGE..... 58

GILENYA ORAL CAPSULE 0.5 MG..... 93

GILOTRIF 112, 113, 114

GLASSIA..... 6

glatiramer acetate 93

GLATOPA 93

glyburide micronized oral tablet 1.5 mg, 3
mg, 6 mg 62, 63

glyburide oral tablet 1.25 mg, 2.5 mg, 5 mg
..... 62, 63

glyburide-metformin oral tablet 1.25-250
mg, 2.5-500 mg 62, 63

glyburide-metformin oral tablet 5-500 mg
..... 62, 63

GOCOVRI 57

granisetron hcl oral tablet 1 mg 200

GRANIX..... 187

guanfacine hcl er 62, 63

guanfacine hcl oral..... 62, 63

H

HAEGARDA 17

heparin sodium (porcine) injection solution
1000 unit/ml, 10000 unit/ml, 5000 unit/ml
..... 201

HEPLISAV-B INTRAMUSCULAR
SOLUTION PREFILLED SYRINGE 20
MCG/0.5ML 201

HETLIOZ..... 60

HETLIOZ LQ 60

HUMATROPE INJECTION CARTRIDGE
..... 58

HUMIRA PEDIATRIC CROHNS START
SUBCUTANEOUS PREFILLED
SYRINGE KIT 80 MG/0.8ML, 80
MG/0.8ML & 40MG/0.4ML 69, 70

HUMIRA PEN SUBCUTANEOUS PEN-
INJECTOR KIT 69, 70

HUMIRA PEN-CD/UC/HS STARTER .. 69,
70

HUMIRA PEN-PEDIATRIC UC START
..... 69, 70

HUMIRA PEN-PS/UV/ADOL HS START
SUBCUTANEOUS PEN-INJECTOR
KIT 40 MG/0.8ML 69, 70

HUMIRA PEN-PSOR/UEVIT STARTER
..... 69, 70

HUMIRA SUBCUTANEOUS PREFILLED
SYRINGE KIT 10 MG/0.1ML, 20
MG/0.2ML, 40 MG/0.4ML, 40
MG/0.8ML 69, 70

hydroxyzine hcl oral syrup..... 62, 63

hydroxyzine hcl oral tablet 25 mg, 50 mg 62,
63

hydroxyzine pamoate oral..... 62, 63

I

IBRANCE..... 112, 113, 114

icatibant acetate..... 71

ICLUSIG..... 112, 113, 114

icosapent ethyl 181

IDHIFA 112, 113, 114

ILARIS SUBCUTANEOUS SOLUTION 72

ILUMYA..... 73

imatinib mesylate 112, 113, 114

IMBRUVICA..... 112, 113, 114

imipramine hcl oral 64

imipramine pamoate..... 64

IMOVAX RABIES INTRAMUSCULAR
INJECTABLE 2.5 UNIT/ML 201

INCRELEX..... 74

indomethacin er..... 62, 63

indomethacin oral capsule 25 mg, 50 mg 62,
63

INGREZZA ORAL CAPSULE 40 MG, 80
MG 184

| | | | |
|--|---------------|---|---------------|
| ingrezza oral capsule 60 mg..... | 184 | LENVIMA (10 MG DAILY DOSE) | 112, 113, 114 |
| INGREZZA ORAL CAPSULE THERAPY PACK..... | 184 | LENVIMA (12 MG DAILY DOSE) | 112, 113, 114 |
| INLYTA..... | 112, 113, 114 | LENVIMA (14 MG DAILY DOSE) | 112, 113, 114 |
| INQOVI | 112, 113, 114 | LENVIMA (18 MG DAILY DOSE) | 112, 113, 114 |
| INREBIC..... | 112, 113, 114 | LENVIMA (20 MG DAILY DOSE) | 112, 113, 114 |
| INTRALIPID INTRAVENOUS EMULSION 20 %, 30 % | 201 | LENVIMA (24 MG DAILY DOSE) | 112, 113, 114 |
| INTRON A..... | 75 | LENVIMA (4 MG DAILY DOSE) 112, 113, 114 | |
| INVEGA TRINZA INTRAMUSCULAR SUSPENSION PREFILLED SYRINGE 273 MG/0.88ML, 410 MG/1.32ML, 546 MG/1.75ML, 819 MG/2.63ML | 76 | LENVIMA (8 MG DAILY DOSE) 112, 113, 114 | |
| ipratropium bromide inhalation solution 0.02 % | 201 | LEUKINE INJECTION SOLUTION RECONSTITUTED..... | 187 |
| ipratropium-albuterol inhalation solution 0.5-2.5 (3) mg/3ml | 201 | levalbuterol hcl inhalation nebulization solution 0.31 mg/3ml, 0.63 mg/3ml, 1.25 mg/3ml | 201 |
| IRESSA..... | 112, 113, 114 | lidocaine external patch 5 % | 173 |
| J | | LIVMARLI | 84 |
| JAKAFI..... | 112, 113, 114 | LONSURF | 112, 113, 114 |
| JYNARQUE | 170 | LORBRENA..... | 112, 113, 114 |
| K | | LUCEMYRA | 85 |
| KALYDECO..... | 77 | LUMAKRAS | 112, 113, 114 |
| KESIMPTA..... | 93 | LUPKYNIS..... | 86 |
| ketorolac tromethamine oral | 62, 63 | LUPRON DEPOT (1-MONTH)..... | 56 |
| KEVEYIS | 78 | LUPRON DEPOT (3-MONTH)..... | 56 |
| KEVZARA | 79 | LUPRON DEPOT (4-MONTH)..... | 56 |
| KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE | 80 | LUPRON DEPOT (6-MONTH)..... | 56 |
| KISQALI (200 MG DOSE) | 112, 113, 114 | LUPRON DEPOT-PED (1-MONTH) INTRAMUSCULAR KIT 7.5 MG | 56 |
| KISQALI (400 MG DOSE) | 112, 113, 114 | LUPRON DEPOT-PED (3-MONTH) INTRAMUSCULAR KIT 11.25 MG (PED) | 56 |
| KISQALI (600 MG DOSE) | 112, 113, 114 | lybalvi | 87 |
| KISQALI FEMARA (400 MG DOSE) . | 112, 113, 114 | LYNPARZA ORAL TABLET 112, 113, 114 | |
| KISQALI FEMARA (600 MG DOSE) . | 112, 113, 114 | M | |
| KISQALI FEMARA(200 MG DOSE) .. | 112, 113, 114 | mavyret oral packet..... | 88 |
| KORLYM | 81 | MAVYRET ORAL TABLET..... | 88 |
| KOSELUGO | 112, 113, 114 | MAYZENT | 93 |
| KYNMOBI | 82 | MAYZENT STARTER PACK..... | 93 |
| L | | megestrol acetate oral suspension 40 mg/ml, 400 mg/10ml, 625 mg/5ml..... | 62, 63 |
| LAMPIT | 83 | | |
| lapatinib ditosylate | 112, 113, 114 | | |
| lenalidomide..... | 112, 113, 114 | | |

| | | | |
|--|---------------|---|---------------|
| megestrol acetate oral tablet..... | 64 | NITYR | 102 |
| MEKINIST | 112, 113, 114 | NIVESTYM INJECTION SOLUTION | |
| MEKTOVI | 112, 113, 114 | PREFILLED SYRINGE | 187 |
| MENEST ORAL TABLET 0.3 MG, 0.625 | | NORDITROPIN FLEXPRO | |
| MG, 1.25 MG..... | 64 | SUBCUTANEOUS SOLUTION PEN- | |
| meperidine hcl oral solution..... | 62, 63 | INJECTOR..... | 58 |
| meperidine hcl oral tablet 50 mg | 62, 63 | NORPACE CR..... | 62, 63 |
| metaxalone oral tablet 800 mg | 67 | NOXAFIL ORAL SUSPENSION | 104 |
| methadone hcl oral tablet 10 mg | 61 | NUBEQA..... | 112, 113, 114 |
| methocarbamol oral | 67 | NUCALA | 105 |
| methoxsalen rapid | 89 | NUEDEXTA..... | 106 |
| methyl dopa oral | 62, 63 | NULOJIX INTRAVENOUS SOLUTION | |
| methyltestosterone oral | 90 | RECONSTITUTED 250 MG | 201 |
| metyrosine..... | 91 | NUPLAZID ORAL CAPSULE..... | 107 |
| miglustat..... | 92 | NUPLAZID ORAL TABLET 10 MG.... | 107 |
| modafinil | 103 | NURTEC..... | 108 |
| morphine sulfate er oral tablet extended | | NUTRILIPID INTRAVENOUS | |
| release 100 mg, 200 mg | 61 | EMULSION 20 %..... | 201 |
| mycophenolate mofetil oral capsule 250 mg | | NUTROPIN AQ NUSPIN 10 | |
| | 201 | SUBCUTANEOUS SOLUTION PEN- | |
| mycophenolate mofetil oral suspension | | INJECTOR..... | 58 |
| reconstituted 200 mg/ml | 201 | NUTROPIN AQ NUSPIN 20 | |
| mycophenolate mofetil oral tablet 500 mg | | SUBCUTANEOUS SOLUTION PEN- | |
| | 201 | INJECTOR..... | 58 |
| mycophenolate sodium oral tablet delayed | | NUTROPIN AQ NUSPIN 5 | |
| release 180 mg, 360 mg | 201 | SUBCUTANEOUS SOLUTION PEN- | |
| MYFEMBREE..... | 94 | INJECTOR..... | 58 |
| N | | NYVEPRIA | 187 |
| nalbuphine hcl injection solution 10 mg/ml | | O | |
| | 201 | OCALIVA..... | 109 |
| NATPARA..... | 96 | ODOMZO | 112, 113, 114 |
| NAYZILAM | 95 | OFEV | 110 |
| NERLYNX | 112, 113, 114 | OLUMIANT ORAL TABLET 1 MG, 2 MG | |
| NEULASTA ONPRO..... | 187 | | 111 |
| NEULASTA SUBCUTANEOUS | | OMNITROPE SUBCUTANEOUS | |
| SOLUTION PREFILLED SYRINGE | 187 | SOLUTION CARTRIDGE..... | 58 |
| NEUPOGEN INJECTION SOLUTION 300 | | OMNITROPE SUBCUTANEOUS | |
| MCG/ML, 480 MCG/1.6ML | 187 | SOLUTION RECONSTITUTED..... | 58 |
| NEUPOGEN INJECTION SOLUTION | | ondansetron hcl oral solution 4 mg/5ml.. | 201 |
| PREFILLED SYRINGE | 187 | ondansetron hcl oral tablet 24 mg, 4 mg, 8 | |
| NEXAVAR | 112, 113, 114 | mg | 201 |
| NEXLETOL..... | 97, 98 | ondansetron oral tablet dispersible 4 mg, 8 | |
| NEXLIZET | 99, 100 | mg | 201 |
| nifedipine oral | 62, 63 | ONUREG..... | 112, 113, 114 |
| NINLARO..... | 112, 113, 114 | ORENCIA CLICKJECT..... | 116 |
| nitisinone..... | 101 | ORENCIA INTRAVENOUS | 116 |

ORENCIA SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 116
 ORFADIN ORAL CAPSULE 20 MG.... 101
 ORFADIN ORAL SUSPENSION..... 101
 ORGOVYX..... 112, 113, 114
 ORLISSA..... 117
 ORKAMBI..... 118
 ORLADEYO..... 119
 orphenadrine citrate er 67
 OTEZLA 120
 OXBRYTA 121
 OXERVATE 122
 oxycodone hcl er oral tablet er 12 hour
 abuse-deterrent..... 61, 123
P
 paliperidone er oral tablet extended release
 24 hour 1.5 mg, 3 mg, 6 mg, 9 mg..... 124
 panretin 171
 PEGASYS SUBCUTANEOUS SOLUTION
 180 MCG/ML 127
 pegasys subcutaneous solution prefilled
 syringe..... 127
 PEMAZYRE 112, 113, 114
 penicillamine oral tablet..... 33
 pentamidine isethionate inhalation solution
 reconstituted 300 mg..... 201
 pentamidine isethionate injection 128
 pentazocine-naloxone hcl..... 62, 63
 PERFOROMIST INHALATION
 NEBULIZATION SOLUTION 20
 MCG/2ML 201
 perphenazine-amitriptyline 64
 PERSERIS 129
 phenobarbital oral elixir 64
 phenobarbital oral tablet 64
 phenoxybenzamine hcl oral 130
 PIQRAY (200 MG DAILY DOSE)112, 113,
 114
 PIQRAY (250 MG DAILY DOSE)112, 113,
 114
 PIQRAY (300 MG DAILY DOSE)112, 113,
 114
 pirfenidone 46
 PLENAMINE INTRAVENOUS
 SOLUTION 15 % 201
 POMALYST 112, 113, 114

PONVORY 93
 PONVORY STARTER PACK..... 93
 posaconazole 104
 PRALUENT SUBCUTANEOUS
 SOLUTION AUTO-INJECTOR 125, 126
 prehevbrio intramuscular suspension 10
 mcg/ml 201
 pretomanid 131
 PREVYMIS ORAL 132
 PRIVIGEN INTRAVENOUS SOLUTION
 10 GM/100ML, 20 GM/200ML, 40
 GM/400ML, 5 GM/50ML 201
 PROCRIT 45
 PROGRAF INTRAVENOUS SOLUTION 5
 MG/ML..... 201
 PROGRAF ORAL PACKET 0.2 MG, 1 MG
 201
 PROLASTIN-C..... 6
 PROLIA SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 133
 PROMACTA ORAL PACKET 134
 PROMACTA ORAL TABLET 134
 promethazine hcl oral..... 62, 63
 promethazine hcl rectal suppository 12.5
 mg, 25 mg 62, 63
 promethazine vc 62, 63
 promethazine-phenylephrine..... 62, 63
 PROMETHEGAN RECTAL
 SUPPOSITORY 50 MG 62, 63
 protriptyline hcl..... 64
 pulmozyme inhalation solution 2.5
 mg/2.5ml 201
 PYRUKYND 135
 PYRUKYND TAPER PACK..... 135
Q
 QINLOCK..... 112, 113, 114
R
 RABAVERT INTRAMUSCULAR
 SUSPENSION RECONSTITUTED... 201
 RAVICTI 136
 REBIF REBIDOSE SUBCUTANEOUS
 SOLUTION AUTO-INJECTOR 93
 REBIF REBIDOSE TITRATION PACK
 SUBCUTANEOUS SOLUTION AUTO-
 INJECTOR..... 93

REBIF SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 93
 REBIF TITRATION PACK
 SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 93
 RECOMBIVAX HB INJECTION
 SUSPENSION 10 MCG/ML, 10
 MCG/ML (1ML SYRINGE), 40
 MCG/ML, 5 MCG/0.5ML 201
 RECORLEV 137
 REGRANEX 138
 RELISTOR ORAL 139
 RELISTOR SUBCUTANEOUS
 SOLUTION 139
 REPATHA 125, 126
 REPATHA PUSHTRONEX SYSTEM. 125,
 126
 REPATHA SURECLICK 125, 126
 RETACRIT INJECTION SOLUTION
 10000 UNIT/ML, 10000
 UNIT/ML(1ML), 2000 UNIT/ML, 20000
 UNIT/ML, 3000 UNIT/ML, 4000
 UNIT/ML, 40000 UNIT/ML 45
 RETEVMO 112, 113, 114
 REVLIMID ORAL CAPSULE 2.5 MG, 20
 MG 112, 113, 114
 REXULTI 140
 REZUROCK 141
 RINVOQ ORAL TABLET EXTENDED
 RELEASE 24 HOUR 15 MG, 30 MG 142
 rinvoq oral tablet extended release 24 hour
 45 mg 142
 ROZLYTREK 112, 113, 114
 RUBRACA 112, 113, 114
 rufinamide oral suspension 11
 rufinamide oral tablet 11
 RYDAPT 112, 113, 114
 RYLAZE 143
S
 SANDIMMUNE ORAL SOLUTION 100
 MG/ML 201
 sapropterin dihydrochloride oral packet . 144
 sapropterin dihydrochloride oral tablet... 144
 SCEMBLIX 112, 113, 114
 SECUADO 145

SEROSTIM SUBCUTANEOUS
 SOLUTION RECONSTITUTED 4 MG,
 5 MG, 6 MG 146
 SIGNIFOR 147
 sildenafil citrate oral suspension
 reconstituted 148
 sildenafil citrate oral tablet 20 mg 148
 SILIQ 149
 SIMPONI SUBCUTANEOUS SOLUTION
 AUTO-INJECTOR 150
 SIMPONI SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 150
 sirolimus oral solution 1 mg/ml 201
 sirolimus oral tablet 0.5 mg, 1 mg, 2 mg 201
 SIRTURO 151
 SKYRIZI (150 MG DOSE) 152
 SKYRIZI PEN 152
 SKYRIZI SUBCUTANEOUS SOLUTION
 PREFILLED SYRINGE 152
 SKYTROFA 58
 sodium phenylbutyrate oral powder 3 gm/tsp
 153
 sodium phenylbutyrate oral tablet 153
 sofosbuvir-velpatasvir 154
 SOMAVERT 155
 sorafenib tosylate 112, 113, 114
 SPRYCEL 112, 113, 114
 STELARA SUBCUTANEOUS
 SOLUTION 45 MG/0.5ML 156
 STELARA SUBCUTANEOUS
 SOLUTION PREFILLED SYRINGE 156
 STIVARGA 113, 114
 SUCRAID 157
 sunitinib malate 113, 114
 SYMDEKO 158
 SYMLINPEN 120 SUBCUTANEOUS
 SOLUTION PEN-INJECTOR 159
 SYMLINPEN 60 SUBCUTANEOUS
 SOLUTION PEN-INJECTOR 159
 SYMPAZAN 26
 SYNAREL 160
 SYNDROS 161
 SYNRIPO 162
T
 TABLOID 113, 114
 TABRECTA 113, 114

tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg 201
 201
 tadalafil (pah) 163
 TAFINLAR 113, 114
 TAGRISSO 113, 114
 TALTZ 164
 TALZENNA ORAL CAPSULE 0.25 MG, 1
 MG 113, 114
 talzenna oral capsule 0.5 mg, 0.75 mg... 113,
 114
 TARGRETIN EXTERNAL 171
 TARPEYO 165
 TASIGNA 113, 114
 TAVNEOS 166
 TAZVERIK 113, 114
 TDVAX INTRAMUSCULAR
 SUSPENSION 2-2 LF/0.5ML 201
 TEFLARO 167
 temazepam 68
 TEPMETKO 113, 114
 teriparatide (recombinant) 168
 testosterone transdermal gel 12.5 mg/act
 (1%), 20.25 mg/1.25gm (1.62%), 25
 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%),
 50 mg/5gm (1%) 172
 testosterone transdermal solution 172
 tetanus-diphtheria toxoids td intramuscular
 suspension 2-2 lf/0.5ml 201
 tetrabenazine 184
 THALOMID 113, 114
 THIOLA EC 169
 TIBSOVO 113, 114
 tiopronin oral 169
 tobramycin inhalation nebulization solution
 300 mg/5ml 201
 tolvaptan 170
 toremifene citrate 113, 114
 TRELSTAR MIXJECT 56
 TREMFYA 174
 trientine hcl 175
 trihexyphenidyl hcl 62, 63
 TRIKAFTA 176
 trimipramine maleate oral 64
 truseltiq (100mg daily dose) 113, 114
 truseltiq (125mg daily dose) 113, 114
 truseltiq (50mg daily dose) 113, 114

truseltiq (75mg daily dose) 113, 114
 TUKYSA 113, 114
 TURALIO 113, 114
 TYMLOS 177
U
 UBRELVY 178
 UDENYCA 187
 UKONIQ 113, 114
 UPTRAVI ORAL 179
V
 VALCHLOR 180
 VALTOCO 10 MG DOSE 95
 VALTOCO 15 MG DOSE 95
 VALTOCO 20 MG DOSE 95
 VALTOCO 5 MG DOSE 95
 VASCEPA ORAL CAPSULE 0.5 GM .. 181
 VENCLEXTA 113, 114
 VENCLEXTA STARTING PACK 113, 114
 VENTAVIS 182
 VERZENIO 113, 114
 vigabatrin 183
 VITRAKVI 113, 114
 VIZIMPRO 113, 114
 vonjo 113, 114
 voriconazole intravenous 185
 VOSEVI 186
 VOTRIENT 113, 114
 VRAYLAR ORAL CAPSULE 115
 VRAYLAR ORAL CAPSULE THERAPY
 PACK 115
W
 welireg 113, 114
X
 XALKORI 113, 114
 XATMEP 188
 XELJANZ 189
 XELJANZ XR 189
 XERMELO 190
 XGEVA 191
 XIFAXAN 192
 XOLAIR 193, 194
 XOSPATA 113, 114
 XPOVIO (100 MG ONCE WEEKLY).. 113,
 114
 XPOVIO (40 MG ONCE WEEKLY).... 113,
 114

| | | | |
|--------------------------------|----------|---|----------|
| XPOVIO (40 MG TWICE WEEKLY).. | 113, 114 | ZELBORAF | 113, 114 |
| XPOVIO (60 MG ONCE WEEKLY).... | 113, 114 | ZEMAIRA | 6 |
| XPOVIO (60 MG TWICE WEEKLY).. | 113, 114 | ZEPOSIA | 93 |
| XPOVIO (80 MG ONCE WEEKLY).... | 113, 114 | ZEPOSIA 7-DAY STARTER PACK..... | 93 |
| XPOVIO (80 MG TWICE WEEKLY).. | 113, 114 | ZEPOSIA STARTER KIT..... | 93 |
| XTANDI | 113, 114 | ZIEXTENZO | 187 |
| XURIDEN..... | 195 | ziprasidone mesylate intramuscular solution | |
| XYREM | 196 | reconstituted 20 mg..... | 201 |
| XYWAV | 197 | ZOLINZA | 113, 114 |
| Y | | zolpidem tartrate er | 68 |
| YONSA..... | 113, 114 | zolpidem tartrate oral tablet 10 mg | 68 |
| Z | | ZTALMY | 198 |
| zaleplon..... | 68 | ZTLIDO | 173 |
| ZARXIO | 187 | ZYDELIG | 113, 114 |
| ZEJULA..... | 113, 114 | ZYKADIA ORAL TABLET | 113, 114 |
| | | ZYPREXA RELPREVV | |
| | | INTRAMUSCULAR SUSPENSION | |
| | | RECONSTITUTED 210 MG, 300 MG, | |
| | | 405 MG | 199 |